



10/500530  
PCT/EP 02/14902

14 MAR 2003  
01 JUL 2004



INVESTOR IN PEOPLE

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 27 MAR 2003

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

*P. Llewellyn*  
20 January 2003



03JAN02 E685083-1 C69803  
01/7700 0.00-0200025.5

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office  
Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

MJL/ND/B45292

2. Patent application number

(The Patent Office will fill in his part)

02 JAN 2002

0200025.5

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

GlaxoSmithKline Biologicals s.a.  
Rue de l'Institut 89, B-1330 Rixensart, Belgium

Patents ADP number (*if you know it*) 08101271001

Belgian

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

Novel Compounds

5. Name of your agent (*if you have one*)

Corporate Intellectual Property

"Address for service" in the United Kingdom to which all correspondence should be sent  
(*including the postcode*)

GlaxoSmithKline  
Two New Horizons Court  
BRENTFORD  
Middlesex TW8 9EP

Patents ADP number (*if you know it*) 07960982002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (*if you know it*) the or each application number

Country	Priority application number ( <i>if you know it</i> )	Date of filing ( <i>day / month / year</i> )
---------	--	---

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing ( <i>day / month / year</i> )
-------------------------------	---

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer yes if:*

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is named as an applicant, or
  - c) any named applicant is a corporate body
- See note (d)

## Novel Compounds

### FIELD OF THE INVENTION

This invention relates to polynucleotides, (herein referred to as "BASB231 polynucleotide(s)"), polypeptides encoded by them (referred to herein as "BASB231" or "BASB231 polypeptide(s)"), recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including vaccines against bacterial infections. In a further aspect, the invention relates to diagnostic assays for detecting infection of certain pathogens.

### BACKGROUND OF THE INVENTION

*Haemophilus influenzae* is a non-motile Gram negative bacterium. Man is its only natural host.

*H. influenzae* isolates are usually classified according to their polysaccharide capsule. Six different capsular types designated a through f have been identified. Isolates that fail to agglutinate with antisera raised against one of these six serotypes are classified as non typeable, and do not express a capsule.

The *H. influenzae* type b is clearly different from the other types in that it is a major cause of bacterial meningitis and systemic diseases. non typeable *H. influenzae* (NTHi) are only occasionally isolated from the blood of patients with systemic disease.

NTHi is a common cause of pneumonia, exacerbation of chronic bronchitis, sinusitis and otitis media.

Otitis media is an important childhood disease both by the number of cases and its potential sequelae. More than 3.5 millions cases are recorded every year in the United States, and it is estimated that 80 % of children have experienced at least one episode of otitis before reaching the age of 3 (1). Left untreated, or becoming chronic, this disease may lead to hearing loss that can be temporary (in the case of fluid accumulation in the

B45292

(17) is highly similar to the Hsf adhesin expressed by *H. influenzae* type b strains (18).

Another protein, the Hap protein shows similarity to IgA1 serine proteases and has been shown to be involved in both adhesion and cell entry (19).

- 5 Five major outer membrane proteins (OMP) have been identified and numerically numbered.

Original studies using *H. influenzae* type b strains showed that antibodies specific for P1 and P2 protected infant rats from subsequent challenge (20-21). P2 was found to be able  
10 to induce bactericidal and opsonic antibodies, which are directed against the variable regions present within surface exposed loop structures of this integral OMP (22-23). The lipoprotein P4 also could induce bactericidal antibodies (24).

P6 is a conserved peptidoglycan-associated lipoprotein making up 1-5 % of the outer  
15 membrane (25). Later a lipoprotein of about the same mol. wt. was recognized, called PCP (P6 crossreactive protein) (26). A mixture of the conserved lipoproteins P4, P6 and PCP did not reveal protection as measured in a chinchilla otitis-media model (27). P6 alone appears to induce protection in the chinchilla model (28).

20 P5 has sequence homology to the integral *Escherichia coli* OmpA (29-30). P5 appears to undergo antigenic drift during persistent infections with NTHi (31). However, conserved regions of this protein induced protection in the chinchilla model of otitis media.

25 In line with the observations made with gonococci and meningococci, NTHi expresses a dual human transferrin receptor composed of TbpA and TbpB when grown under iron limitation. Anti-TbpB protected infant rats. (32). Hemoglobin / haptoglobin receptors have also been described for NTHi (33). A receptor for Haem: Hemopexin has also been identified (34). A lactoferrin receptor is also present in NTHi, but is not yet characterized  
30 (35).

18. St. Geme, JW. et al. (1996) *J. Bact.* 178:6281
19. St. Geme, JW. et al. (1994) *Mol. Microbiol.* 14:217
20. Loeb, MR. et al. (1987) *Infect. Immun.* 55:2612
21. Musson, RS. Jr. et al. (1983) *J. Clin. Invest.* 72:677
- 5 22. Haase, EM. et al. (1994) *Infect. Immun.* 62:3712
23. Troelstra, A. et al. (1994) *Infect. Immun.* 62:779
24. Green, BA. et al. (1991) *Infect. Immun.* 59:3191
25. Nelson, MB. et al. (1991) *Infect. Immun.* 59:2658
26. Deich, RM. et al. (1990) *Infect. Immun.* 58:3388
- 10 27. Green, BA. et al. (1993) *Infect. Immun.* 61:1950
28. Demaria, TF. et al. (1996) *Infect. Immun.* 64:5187
29. Miyamoto, N., Bakaletz, LO (1996) *Microb. Pathog.* 21:343
30. Munson, RS.jr. et al. (1993) *Infect. Immun.* 61:1017
31. Duim, B. et al. (1997) *Infect. Immun.* 65:1351
- 15 32. Loosmore, SM. et al (1996) *Mol. Microbiol.* 19:575
33. Maciver, I. et al. (1996) *Infect. Immun.* 64:3703
34. Cope, LD. et al. (1994) *Mol. Microbiol.* 13:868
35. Schryvers, AB. et al. (1989) *J. Med. Microbiol.* 29:121
36. Flack, FS. et al. (1995) *Gene* 156:97
- 20 37. Akkoyunlu, M. et al. (1996) *Infect. Immun.* 64:4586
38. Kimura, A. et al. (1985) *Infect. Immun.* 47:253
39. Mulks, MH. et Shoberg, RJ (1994) *Meth. Enzymol.* 235:543
40. Lomholt, H. Alphen, Lv, Kilian, M. (1993) *Infect. Immun.* 61:4575
41. Kyd, J.M. and Cripps, A.W. (1998) *Infect. Immun.* 66:2272
- 25 42. Loosmore, S.M. et al. (1998) *Infect. Immun.* 66:899

The frequency of NTHi infections has risen dramatically in the past few decades. This phenomenon has created an unmet medical need for new anti-microbial agents, vaccines, drug screening methods and diagnostic tests for this organism. The present invention

30 aims to meet that need.

					<i>influenzae</i> (74%)
Orf4	726	241	7	8	Molybdenum ABC transporter, periplasmic molybdate-binding protein, <i>Deinococcus radiodurans</i> (26%)
Orf5	741	246	9	10	ABC transporter, <i>Haemophilus influenzae</i> (38%)
Orf6	1023	340	11	12	ABC transporter, <i>Haemophilus influenzae</i> (45%)
Orf7	942	313	13	14	ABC transporter, <i>Haemophilus influenzae</i> (56%)
Orf8	558	185	15	16	Invasin precursor (YadA c-term), <i>Yersinia enterocolitica</i> (27%)
Orf9	2373	790	17	18	DNA methylase hsdm, <i>Vibrio cholerae</i> (70%)
Orf10	818	272	19	20	Leucyl tRNA synthetase, <i>Borrelia burgdorferi</i> (28%)
Orf11	636	211	21	22	ATP dependant DNA helicase, <i>Deinococcus radiodurans</i> (37%)
Orf12	1257	418	23	24	Type I restriction-modification system (s subunit), <i>Caulobacter crescentus</i> (29%)
Orf13	3027	1008	25	26	Type I restriction enzyme hsdR, <i>Vibrio cholerae</i> (65%)
Orf14	2052	683	27	28	Probable aaa family atpase, <i>Campylobacter jejuni</i> (33%)
Orf15	975	324	29	30	No homology with known protein
Orf16	744	247	31	32	Hypothetical 29.0 kd protein, <i>Aquifex aeolicus</i> (24%)
Orf17	846	271	33	34	Hypothetical 27.0 kd protein, <i>Aquifex aeolicus</i> (30%)
Orf18	273	90	35	36	Cell division protein ftsK (C-term), <i>Escherichia coli</i> (46%)
Orf19	1023	340	37	38	Putative dna-binding protein, <i>Neisseria meningitidis</i> (45%)
Orf20	711	236	39	40	Hypothetical 22.9 kd protein, <i>Actinobacillus actinomycetemcomitans</i> (79%)
Orf21	456	151	41	42	Yors protein, <i>Bacillus subtilis</i> (26%)
Orf22	441	146	43	44	Phosphate transport atp-binding protein pstB homolog, <i>Mycoplasma genitalium</i> (24%)
Orf23	642	213	45	46	No homology with known protein
Orf24	1344	447	47	48	Type I restriction protein, <i>Haemophilus influenzae</i> (40%)
Orf25	1995	664	49	50	Hypothetical 84.7 kda protein, <i>Thermotoga maritima</i> (25%)
Orf26	1155	384	51	52	Anticodon nuclease, <i>Neisseria meningitidis</i> (61%)
Orf27	999	332	53	54	wkue. gp8 protein, <i>wolbachia</i> sp. (40 %)
Orf28	819	272	55	56	Putative transposase protein, <i>Rhizobium meliloti</i> (40%)
Orf29	333	110	57	58	Partial sequence of <i>Bacteriophage</i> <i>ifl</i> . orf348 (35%)
Orf30	261	86	59	60	Putative cytoplasmic protein, <i>Salmonella typhimurium</i> lt2 (27%)
Orf31	927	308	61	62	Tryptophan 2-monooxygenase, <i>Agrobacterium</i>

membrane, or as purified LOS). In addition the enzyme may be isolated or recombinantly produced for its specific function to be used in vitro to produce novel synthetic oligosaccharide structures.

- 5 It is understood that sequences recited in the Sequence Listing below as "DNA" represent an exemplification of one embodiment of the invention, since those of ordinary skill will recognize that such sequences can be usefully employed in polynucleotides in general, including ribopolynucleotides.

The sequences of the BASB231 polynucleotides are set out in SEQ ID NO:1, 3, 5, 7, 9,  
10 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73. SEQ Group 1 refers herein to any one of the polynucleotides set out in SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71 or 73.

The sequences of the BASB231 encoded polypeptides are set out in SEQ ID NO:2, 4, 6, 8,  
15 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72. SEQ Group 2 refers herein to any one of the encoded polypeptides set out in SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70 or 72.

## 20 Polypeptides

In one aspect of the invention there are provided polypeptides of non typeable *H. influenzae* referred to herein as "BASB231" and "BASB231 polypeptides" as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

25

The present invention further provides for:

- (a) an isolated polypeptide which comprises an amino acid sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% or exact identity, to that of any sequence of SEQ Group 2;
- 30 (b) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence which has at least 85% identity, preferably at least 90% identity, more preferably

Preferred fragments include, for example, truncation polypeptides having a portion of an amino acid sequence selected from SEQ Group 2 or of variants thereof, such as a continuous series of residues that includes an amino- and/or carboxyl-terminal amino acid sequence. Degradation forms of the polypeptides of the invention produced by or in a host cell, are also preferred. Further preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

Further preferred fragments include an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from an amino acid sequence selected from SEQ Group 2 or an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids truncated or deleted from an amino acid sequence selected from SEQ Group 2.

Still further preferred fragments are those which comprise a B-cell or T-helper epitope, for example those fragments/peptides described in Example 10.

Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these fragments may be employed as intermediates for producing the full-length polypeptides of the invention.

Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

The polypeptides, or immunogenic fragments, of the invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in

*Streptococcus pneumoniae* which synthesize an N-acetyl-L-alanine amidase, amidase LytA, (coded by the *lytA* gene {Gene, 43 (1986) page 265-272}) an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LytA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of *E.coli* C-LytA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LytA fragment at its amino terminus has been described {Biotechnology: 10, (1992) page 795-798}. It is possible to use the repeat portion of the LytA molecule found in the C terminal end starting at residue 178, for example residues 188 - 305.

The present invention also includes variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr.

Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

It is most preferred that a polypeptide of the invention is derived from non typeable *H. influenzae*, however, it may preferably be obtained from other organisms of the same taxonomic genus. A polypeptide of the invention may also be obtained, for example, from organisms of the same taxonomic family or order.

### Polynucleotides

B45292

strain 3224A cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as a polynucleotide sequence given in SEQ Group 1, typically a library of clones of chromosomal DNA of non typeable *H. influenzae* strain 3224A in *E. coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent hybridization conditions. By sequencing the individual clones thus identified by hybridization with sequencing primers designed from the original polypeptide or polynucleotide sequence it is then possible to extend the polynucleotide sequence in both directions to determine a full length gene sequence. Conveniently, such sequencing is performed, for example, using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Direct genomic DNA sequencing may also be performed to obtain a full length gene sequence. Illustrative of the invention, each polynucleotide set out in SEQ Group 1 was discovered in a DNA library derived from non typeable *H. influenzae*.

Moreover, each DNA sequence set out in SEQ Group 1 contains an open reading frame encoding a protein having about the number of amino acid residues set forth in SEQ Group 2 with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known to those skilled in the art.

The polynucleotides of SEQ Group 1, between the start codon and the stop codon, encode respectively the polypeptides of SEQ Group 2. The nucleotide number of start codon and first nucleotide of stop codon are listed in table 2 for each polynucleotide of SEQ Group 1.

Table 2

Name	Start codon	1 <sup>st</sup> nucleotide of Stop codon
------	-------------	--

B45292

(a) a polynucleotide sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, even more preferably at least 97-99% or exact identity, to any polynucleotide sequence from SEQ Group 1 over the entire length of the polynucleotide sequence from SEQ Group 1; or

(b) a polynucleotide sequence encoding a polypeptide which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, even more preferably at least 97-99% or 100% exact identity, to any amino acid sequence selected from SEQ Group 2, over the entire length of the amino acid sequence from SEQ Group 2.

A polynucleotide encoding a polypeptide of the present invention, including homologs and orthologs from species other than non typeable *H. influenzae*, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions (for example, using a temperature in the range of 45 – 65°C and an SDS

concentration from 0.1 – 1%) with a labeled or detectable probe consisting of or comprising any sequence selected from SEQ Group 1 or a fragment thereof; and isolating a full-length gene and/or genomic clones containing said polynucleotide sequence.

The invention provides a polynucleotide sequence identical over its entire length to a coding sequence (open reading frame) set out in SEQ Group 1. Also provided by the invention is a coding sequence for a mature polypeptide or a fragment thereof, by itself as well as a coding sequence for a mature polypeptide or a fragment in reading frame with another coding sequence, such as a sequence encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence. The polynucleotide of the invention may also contain at least one non-coding sequence, including for example, but not limited to at least one non-coding 5' and 3' sequence, such as the transcribed but non-translated sequences, termination signals (such as rho-dependent and rho-independent termination signals), ribosome binding sites, Kozak sequences, sequences that stabilize mRNA, introns, and polyadenylation signals.

The polynucleotide sequence may also comprise additional coding sequence encoding additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker

Orf25	1	1992
Orf26	1*	1152
Orf27	1	996
Orf28	1	816
Orf29	1*	330
Orf30	1	258
Orf31	1	915
Orf32	1*	309
Orf33	1	1461
Orf34	1	885
Orf35	1*	840
Orf36	1*	390
Orf37	1	672

\*It is not the start codon but it is the first nucleotide of the coding sequence

The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the non typeable *H. influenzae* BASB231 having an amino acid sequence set out in any of the sequences of SEQ Group 2 .

The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, polynucleotides interrupted by integrated phage, an integrated insertion sequence, an integrated vector sequence, an integrated transposon sequence, or due to RNA editing or genomic DNA reorganization) together with additional regions, that also may contain coding and/or non-coding sequences.

The invention further relates to variants of the polynucleotides described herein that encode variants of a polypeptide having a deduced amino acid sequence of any of the sequences of SEQ Group 2 . Fragments of polynucleotides of the invention may be used, for example, to synthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encoding BASB231 variants, that have the amino acid sequence of BASB231 polypeptide of any sequence from SEQ Group 2 in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, modified, deleted and/or added, in any combination. Especially preferred

solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at about 65°C.

Hybridization and wash conditions are well known and exemplified in Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y.,

(1989), particularly Chapter 11 therein. Solution hybridization may also be used with the polynucleotide sequences provided by the invention.

The invention also provides a polynucleotide consisting of or comprising a polynucleotide sequence obtained by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in any of the sequences of SEQ Group 1 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in the corresponding sequence of SEQ Group 1 or a fragment thereof; and isolating said polynucleotide sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers fully described elsewhere herein.

As discussed elsewhere herein regarding polynucleotide assays of the invention, for instance, the polynucleotides of the invention, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding BASB231 and to isolate cDNA and genomic clones of other genes that have a high identity, particularly high sequence identity, to the BASB231 gene. Such probes generally will comprise at least 15 nucleotide residues or base pairs. Preferably, such probes will have at least 30 nucleotide residues or base pairs and may have at least 50 nucleotide residues or base pairs. Particularly preferred probes will have at least 20 nucleotide residues or base pairs and will have less than 30 nucleotide residues or base pairs.

A coding region of a BASB231 gene may be isolated by screening using a DNA sequence provided in SEQ Group 1 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in vivo*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

For each and every polynucleotide of the invention there is provided a polynucleotide complementary to it. It is preferred that these complementary polynucleotides are fully complementary to each polynucleotide with which they are complementary.

A precursor protein, having a mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In addition to the standard A, G, C, T/U representations for nucleotides, the term "N" may also be used in describing certain polynucleotides of the invention. "N" means that any of the four DNA or RNA nucleotides may appear at such a designated position in the DNA or RNA sequence, except it is preferred that N is not a nucleic acid that when taken in combination with adjacent nucleotide positions, when read in the correct reading frame, would have the effect of generating a premature termination codon in such reading frame.

In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis, *et al.*, *BASIC METHODS IN MOLECULAR BIOLOGY*, (1986) and Sambrook, *et al.*, *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, conjugation, transduction, scrape loading, ballistic introduction and infection.

- 10 Representative examples of appropriate hosts include bacterial cells, such as cells of streptococci, staphylococci, enterococci, *E. coli*, streptomyces, cyanobacteria, *Bacillus subtilis*, *Neisseria meningitidis*, *Haemophilus influenzae* and *Moraxella catarrhalis*; fungal cells, such as cells of a yeast, *Kluveromyces*, *Saccharomyces*, *Pichia*, a basidiomycete, *Candida albicans* and *Aspergillus*; insect cells such as cells of *Drosophila* S2 and
- 15 *Spodoptera* Sf9; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293, CV-1 and Bowes melanoma cells; and plant cells, such as cells of a gymnosperm or angiosperm.

- A great variety of expression systems can be used to produce the polypeptides of the invention. Such vectors include, among others, chromosomal-, episomal- and virus-derived
- 20 vectors, for example, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses, picornaviruses, retroviruses, and alphaviruses and vectors derived from combinations thereof, such as those derived from
- 25 plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression system constructs may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropriate DNA sequence may be inserted into the expression system by any
- 30 of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, *MOLECULAR CLONING, A LABORATORY MANUAL*, (*supra*).

diagnostic method for diagnosis of disease, staging of disease or response of an infectious organism to drugs. Eukaryotes, particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism comprising the BASB231 gene or protein, may be detected at the nucleic acid or amino acid level by a variety of well known techniques as well as by methods provided herein.

Polypeptides and polynucleotides for prognosis, diagnosis or other analysis may be obtained from a putatively infected and/or infected individual's bodily materials. Polynucleotides from any of these sources, particularly DNA or RNA, may be used directly for detection or may be amplified enzymatically by using PCR or any other amplification technique prior to analysis. RNA, particularly mRNA, cDNA and genomic DNA may also be used in the same ways. Using amplification, characterization of the species and strain of infectious or resident organism present in an individual, may be made by an analysis of the genotype of a selected polynucleotide of the organism. Deletions and insertions can be detected by a change in size of the amplified product in comparison to a genotype of a reference sequence selected from a related organism, preferably a different species of the same genus or a different strain of the same species. Point mutations can be identified by hybridizing amplified DNA to labeled BASB231 polynucleotide sequences. Perfectly or significantly matched sequences can be distinguished from imperfectly or more significantly mismatched duplexes by DNase or RNase digestion, for DNA or RNA respectively, or by detecting differences in melting temperatures or renaturation kinetics. Polynucleotide sequence differences may also be detected by alterations in the electrophoretic mobility of polynucleotide fragments in gels as compared to a reference sequence. This may be carried out with or without denaturing agents. Polynucleotide differences may also be detected by direct DNA or RNA sequencing. See, for example, Myers *et al.*, *Science*, 230: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase, V1 and S1 protection assay or a chemical cleavage method. See, for example, Cotton *et al.*, *Proc. Natl. Acad. Sci., USA*, 85: 4397-4401 (1985).

In another embodiment, an array of oligonucleotides probes comprising BASB231 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening

example. For example, RT-PCR can be used to detect mutations in the RNA. It is particularly preferred to use RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan. RNA, cDNA or genomic DNA may also be used for the same purpose, PCR. As an example, PCR primers complementary to a polynucleotide encoding BASB231 polypeptide can be used to identify and analyze mutations.

The invention further provides primers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end. These primers may be used for, among other things, amplifying BASB231 DNA and/or RNA isolated from a sample derived from an individual, such as a bodily material. The primers may be used to amplify a polynucleotide isolated from an infected individual, such that the polynucleotide may then be subject to various techniques for elucidation of the polynucleotide sequence. In this way, mutations in the polynucleotide sequence may be detected and used to diagnose and/or prognose the infection or its stage or course, or to serotype and/or classify the infectious agent.

The invention further provides a process for diagnosing, disease, preferably bacterial infections, more preferably infections caused by non typeable *H. influenzae*, comprising determining from a sample derived from an individual, such as a bodily material, an increased level of expression of polynucleotide having a sequence of any of the sequences of SEQ Group 1. Increased or decreased expression of BASB231 polynucleotide can be measured using any one of the methods well known in the art for the quantitation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting, spectrometry and other hybridization methods.

In addition, a diagnostic assay in accordance with the invention for detecting over-expression of BASB231 polypeptide compared to normal control tissue samples may be used to detect the presence of an infection, for example. Assay techniques that can be used to determine levels of BASB231 polypeptide, in a sample derived from a host, such as a bodily material, are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis, antibody sandwich assays, antibody detection and ELISA assays.

preparation of monoclonal antibodies, any technique known in the art that provides antibodies produced by continuous cell line cultures can be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, pg. 77-96 in *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc. (1985).

Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to polypeptides or polynucleotides of this invention. Also, transgenic mice, or other organisms or animals, such as other mammals, may be used to express humanized antibodies immunospecific to the polypeptides or polynucleotides of the invention.

Alternatively, phage display technology may be utilized to select antibody genes with binding activities towards a polypeptide of the invention either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-BASB231 or from naive libraries (McCafferty, *et al.*, (1990), *Nature* 348, 552-554; Marks, *et al.*, (1992) *Biotechnology* 10, 779-783). The affinity of these antibodies can also be improved by, for example, chain shuffling (Clackson *et al.*, (1991) *Nature* 352: 628).

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptides or polynucleotides of the invention to purify the polypeptides or polynucleotides by, for example, affinity chromatography.

Thus, among others, antibodies against BASB231 polypeptide or BASB231 polynucleotide may be employed to treat infections, particularly bacterial infections.

Polypeptide variants include antigenically, epitopically or immunologically equivalent variants form a particular aspect of this invention.

Preferably, the antibody or variant thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be

standard. Fusion proteins, such as those made from Fc portion and BASB231 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists of the polypeptide of the present invention, as well as of phylogenetically and and/or functionally related polypeptides (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies that bind to and/or interact with a polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and/or polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of BASB231 polypeptides or polynucleotides, particularly those compounds that are bacteriostatic and/or bactericidal.

The method of screening may involve high-throughput techniques. For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising BASB231 polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a BASB231 agonist or antagonist. The ability of the candidate molecule to agonize or antagonize the BASB231 polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate. Molecules that bind gratuitously, *i.e.*, without inducing the effects of BASB231 polypeptide are most likely to be good antagonists. Molecules that bind well and, as the case may be, increase the rate of product production from substrate, increase signal transduction, or increase chemical channel activity are agonists. Detection of the rate or level of, as the case may be, production of product from substrate, signal transduction, or

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

Each of the polynucleotide sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein, upon expression, can be used as a target for the screening of antibacterial drugs. Additionally, the polynucleotide sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

The invention also provides the use of the polypeptide, polynucleotide, agonist or antagonist of the invention to interfere with the initial physical interaction between a pathogen or pathogens and a eukaryotic, preferably mammalian, host responsible for sequelae of infection. In particular, the molecules of the invention may be used: in the prevention of adhesion of bacteria, in particular gram positive and/or gram negative bacteria, to eukaryotic, preferably mammalian, extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block bacterial adhesion between eukaryotic, preferably mammalian, extracellular matrix proteins and bacterial BASB231 proteins that mediate tissue damage and/or; to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.

capable of binding to anti-native peptide antibodies, but may not necessarily themselves share significant sequence homology to the native polypeptide.

### Vaccines

- 5 Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal, preferably humans, which comprises inoculating the individual with BASB231 polynucleotide and/or polypeptide, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bacterial infection and most
- 10 particularly non typeable *H. influenzae* infection. Also provided are methods whereby such immunological response slows bacterial replication. Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector, sequence or ribozyme to direct expression of BASB231 polynucleotide and/or polypeptide, or a fragment or a
- 15 variant thereof, for expressing BASB231 polynucleotide and/or polypeptide, or a fragment or a variant thereof *in vivo* in order to induce an immunological response, such as, to produce antibody and/ or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual, preferably a human, from disease, whether that disease is already established within the individual or not. One
- 20 example of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a ribozyme, a modified nucleic acid, a DNA/RNA hybrid, a DNA-protein complex or an RNA-protein complex.
- 25 A further aspect of the invention relates to an immunological composition that when introduced into an individual, preferably a human, capable of having induced within it an immunological response, induces an immunological response in such individual to a BASB231 polynucleotide and/or polypeptide encoded therefrom, wherein the composition comprises a recombinant BASB231 polynucleotide and/or polypeptide encoded therefrom
- 30 and/or comprises DNA and/or RNA which encodes and expresses an antigen of said BASB231 polynucleotide, polypeptide encoded therefrom, or other polypeptide of the

B45292

Blebs have the advantage of providing outer-membrane proteins in their native conformation and are thus particularly useful for vaccines. Blebs can also be improved for vaccine use by engineering the bacterium so as to modify the expression of one or more molecules at the outer membrane. Thus for example the expression of a desired immunogenic protein at the outer membrane, such as the BASB231 polypeptide, can be introduced or upregulated (e.g. by altering the promoter). Instead or in addition, the expression of outer-membrane molecules which are either not relevant (e.g. unprotective antigens or immunodominant but variable proteins) or detrimental (e.g. toxic molecules such as LPS, or potential inducers of an autoimmune response) can be downregulated. These approaches are discussed in more detail below.

The non-coding flanking regions of the BASB231 gene contain regulatory elements important in the expression of the gene. This regulation takes place both at the transcriptional and translational level. The sequence of these regions, either upstream or downstream of the open reading frame of the gene, can be obtained by DNA sequencing. This sequence information allows the determination of potential regulatory motifs such as the different promoter elements, terminator sequences, inducible sequence elements, repressors, elements responsible for phase variation, the shine-dalgarno sequence, regions with potential secondary structure involved in regulation, as well as other types of regulatory motifs or sequences. This sequence is a further aspect of the invention.

Furthermore, SEQ ID NO: 75 contains the non typeable *Haemophilus influenzae* polynucleotide sequences not present in the HiRd genome and comprising the ORFs1, 2, 3, 4, 5, 6, 7, 8 and their non-coding flanking regions.

The non-coding flanking regions are located between the ORFs of SED ID NO: 75. The localisation of the ORFs of SED ID NO: 75 are listed in table 4.

Table 4:

Name	Position of the first nucleotide of start codon	Position of the last nucleotide of stop codon	Strand
Orf1	90	542	+

B45292

Orf20	7027	6317	-
Orf21	7467	7011	-
Orf22	7966*	7526	-

\*It is not the first nucleotide of the start codon, it is the first nucleotide of the coding sequence

Furthermore, SEQ ID NO: 78 contains the non typeable *Haemophilus influenzae* polynucleotide sequences not present in the HiRd genome and comprising the ORFs 23, 24 and their non-coding flanking regions.

The non-coding flanking regions are located between the ORFs of SED ID NO: 78. The localisation of the ORFs of SED ID NO: 78 are listed in table 7.

Table 7

Name	Position of the first nucleotide of start codon	Position of the last nucleotide of stop codon	Strand
Orf23	688	47	-
Orf24	2028	685	-

Furthermore, SEQ ID NO: 79 contains the non typeable *Haemophilus influenzae* polynucleotide sequences not present in the HiRd genome and comprising the ORF 25 and their non-coding flanking regions.

The non-coding flanking regions are located between the ORF of SED ID NO: 79. The localisation of the ORF of SED ID NO: 79 are listed in table 8.

Table 8

Name	Position of the first nucleotide of start codon	Position of the last nucleotide of stop codon	Strand
Orf25	2205	211	-

Furthermore, SEQ ID NO: 80 contains the non typeable *Haemophilus influenzae* polynucleotide sequences not present in the HiRd genome and comprising the ORFs 26, 27 and their non-coding flanking regions.

The non-coding flanking regions are located between the ORFs of SED ID NO: 80. The localisation of the ORFs of SED ID NO: 80 are listed in table 9.

Table 9

Name	Position of the first nucleotide of start codon	Position of the last nucleotide of stop codon	Strand
------	---	---	--------

Table 12

Name	Position of the first nucleotide of start codon	Position of the last nucleotide of stop codon	Strand
Orf33	74	1537	+

Furthermore, SEQ ID NO: 84 contains the non typeable *Haemophilus influenzae* polynucleotide sequences not present in the HiRd genome and comprising the ORF 34 and their non-coding flanking regions.

The non-coding flanking regions are located between the ORF of SED ID NO: 84. The localisation of the ORF of SED ID NO: 84 are listed in table 13.

Table 13

Name	Position of the first nucleotide of start codon	Position of the last nucleotide of stop codon	Strand
Orf34	82	969	+

Furthermore, SEQ ID NO: 85 contains the non typeable *Haemophilus influenzae* polynucleotide sequences not present in the HiRd genome and comprising the ORF 35 and their non-coding flanking regions.

The non-coding flanking regions are located between the ORF of SED ID NO: 83. The localisation of the ORF of SED ID NO: 85 are listed in table 13.

Table 13

Name	Position of the first nucleotide of start codon	Position of the last nucleotide of stop codon	Strand
Orf35	1065*	223	-

\*It is not the first nucleotide of the start codon, it is the first nucleotide of the coding sequence

Furthermore, SEQ ID NO: 86 contains the non typeable *Haemophilus influenzae* polynucleotide sequences not present in the HiRd genome and comprising the ORF 36 and their non-coding flanking regions.

The non-coding flanking regions are located between the ORF of SED ID NO: 86. The localisation of the ORF of SED ID NO: 86 are listed in table 14.

Table 14

Name	Position of the first nucleotide of	Position of the last nucleotide of stop	Strand
------	-------------------------------------	---	--------

on gene expression can be assessed. In another approach, the sequence knowledge of the region of interest can be used to replace or delete all or part of the natural regulatory sequences. In this case, the regulatory region targeted is isolated and modified so as to contain the regulatory elements from another gene, a combination of regulatory elements from different genes, a synthetic regulatory region, or any other regulatory region, or to delete selected parts of the wild-type regulatory sequences. These modified sequences can then be reintroduced into the bacterium via homologous recombination into the genome. A non-exhaustive list of preferred promoters that could be used for up-regulation of gene expression includes the promoters *porA*, *porB*, *lbpB*, *tbpB*, *p110*, *lst*, *hpuAB* from *N. meningitidis* or *N. gonorrhoeae*; *ompCD*, *copB*, *lbpB*, *ompE*, *UspA1*; *UspA2*; *TbpB* from *M. Catarrhalis*; *p1*, *p2*, *p4*, *p5*, *p6*, *lpD*, *tbpB*, *D15*, *Hia*, *Hmw1*, *Hmw2* from *H. influenzae*.

In one example, the expression of the gene can be modulated by exchanging its promoter with a stronger promoter (through isolating the upstream sequence of the gene, in vitro modification of this sequence, and reintroduction into the genome by homologous recombination). Upregulated expression can be obtained in both the bacterium as well as in the outer membrane vesicles shed (or made) from the bacterium.

In other examples, the described approaches can be used to generate recombinant bacterial strains with improved characteristics for vaccine applications. These can be, but are not limited to, attenuated strains, strains with increased expression of selected antigens, strains with knock-outs (or decreased expression) of genes interfering with the immune response, strains with modulated expression of immunodominant proteins, strains with modulated shedding of outer-membrane vesicles.

Thus, also provided by the invention is a modified upstream region of the BASB231 gene, which modified upstream region contains a heterologous regulatory element which alters the expression level of the BASB231 protein located at the outer membrane. The upstream region according to this aspect of the invention includes the sequence upstream of the BASB231 gene. The upstream region starts immediately upstream of the BASB231

Such experiments will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value, derived from the requisite organ of the animal successfully resisting or clearing infection, for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly non typeable *H. influenzae* infection, in mammals, particularly humans.

The invention also includes a vaccine formulation which comprises an immunogenic recombinant polypeptide and/or polynucleotide of the invention together with a suitable carrier, such as a pharmaceutically acceptable carrier. Since the polypeptides and polynucleotides may be broken down in the stomach, each is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostatic compounds and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.

The vaccine formulation of the invention may also include adjuvant systems for enhancing the immunogenicity of the formulation. Preferably the adjuvant system raises preferentially a TH1 type of response.

An immune response may be broadly distinguished into two extreme catagories, being a humoral or cell mediated immune responses (traditionally characterised by antibody and cellular effector mechanisms of protection respectively). These categories of response have been termed TH1-type responses (cell-mediated response), and TH2-type immune responses (humoral response).

Thus, a TH1-type adjuvant is one which preferentially stimulates isolated T-cell populations to produce high levels of TH1-type cytokines when re-stimulated with antigen *in vitro*, and promotes development of both CD8+ cytotoxic T lymphocytes and antigen specific immunoglobulin responses associated with TH1-type isotype.

Adjuvants which are capable of preferential stimulation of the TH1 cell response are described in International Patent Application No. WO 94/00153 and WO 95/17209.

3 De-O-acylated monophosphoryl lipid A (3D-MPL) is one such adjuvant. This is known from GB 2220211 (Ribi). Chemically it is a mixture of 3 De-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains and is manufactured by Ribi Immunochem, Montana. A preferred form of 3 De-O-acylated monophosphoryl lipid A is disclosed in European Patent 0 689 454 B1 (SmithKline Beecham Biologicals SA).

Preferably, the particles of 3D-MPL are small enough to be sterile filtered through a 0.22micron membrane (European Patent number 0 689 454).

3D-MPL will be present in the range of 10µg - 100µg preferably 25-50µg per dose wherein the antigen will typically be present in a range 2-50µg per dose.

Another preferred adjuvant comprises QS21, an Hplc purified non-toxic fraction derived from the bark of *Quillaja Saponaria Molina*. Optionally this may be admixed with 3 De-O-acylated monophosphoryl lipid A (3D-MPL), optionally together with an carrier.

The method of production of QS21 is disclosed in US patent No. 5,057,540.

Non-reactogenic adjuvant formulations containing QS21 have been described previously (WO 96/33739). Such formulations comprising QS21 and cholesterol have been shown to be successful TH1 stimulating adjuvants when formulated together with an antigen.

Non-toxic oil in water emulsions preferably contain a non-toxic oil, e.g. squalane or squalene, an emulsifier, e.g. Tween 80, in an aqueous carrier. The aqueous carrier may be, for example, phosphate buffered saline.

- 5 A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil in water emulsion is described in WO 95/17210.

While the invention has been described with reference to certain BASB231 polypeptides and polynucleotides, it is to be understood that this covers fragments of the naturally occurring polypeptides and polynucleotides, and similar polypeptides and polynucleotides with additions, deletions or substitutions which do not substantially affect the immunogenic properties of the recombinant polypeptides or polynucleotides.

10 The present invention also provides a polyvalent vaccine composition comprising a vaccine formulation of the invention in combination with other antigens, in particular antigens useful for treating *otitis media*. Such a polyvalent vaccine composition may include a TH-1 inducing adjuvant as hereinbefore described.

20 In a preferred embodiment, the polypeptides, fragments and immunogens of the invention are formulated with one or more plain or conjugated pneumococcal capsular polysaccharides, and one or more antigens that can protect a host against *M. catarrhalis* infection. Optionally, the vaccine may also comprise one or more protein antigens that can protect a host against *Streptococcus pneumoniae* infection. Optionally, the vaccine may also comprise one or more further non typeable *Haemophilus influenzae* protein antigens.

25 The vaccine may also optionally comprise one or more antigens that can protect a host against RSV and/or one or more antigens that can protect a host against influenza virus. Such a vaccine may be advantageously used as a global otitis media vaccine.

30 The pneumococcal capsular polysaccharide antigens are preferably selected from serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F,

5843464 - Ohio State Research Foundation), OMP26, P6, protein D, TbpA, TbpB, Hia, Hmw1, Hmw2, Hap, and D15.

Preferred influenza virus antigens include whole, live or inactivated virus, split  
5 influenza virus, grown in eggs or MDCK cells, or Vero cells or whole flu virosomes (as  
described by R. Gluck, Vaccine, 1992, 10, 915-920) or purified or recombinant proteins  
thereof, such as HA, NP, NA, or M proteins, or combinations thereof.

Preferred RSV (Respiratory Syncytial Virus) antigens include the F glycoprotein, the G  
10 glycoprotein, the HN protein, or derivatives thereof.

#### **Compositions, kits and administration**

In a further aspect of the invention there are provided compositions comprising a BASB231  
15 polynucleotide and/or a BASB231 polypeptide for administration to a cell or to a  
multicellular organism.

The invention also relates to compositions comprising a polynucleotide and/or a  
polypeptides discussed herein or their agonists or antagonists. The polypeptides and  
20 polynucleotides of the invention may be employed in combination with a non-sterile or  
sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical  
carrier suitable for administration to an individual. Such compositions comprise, for  
instance, a media additive or a therapeutically effective amount of a polypeptide and/or  
polynucleotide of the invention and a pharmaceutically acceptable carrier or excipient. Such  
25 carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol,  
ethanol and combinations thereof. The formulation should suit the mode of administration.  
The invention further relates to diagnostic and pharmaceutical packs and kits comprising  
one or more containers filled with one or more of the ingredients of the aforementioned  
compositions of the invention.

30

For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.

Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

#### **Sequence Databases, Sequences in a Tangible Medium, and Algorithms**

Polynucleotide and polypeptide sequences form a valuable information resource with which to determine their 2- and 3-dimensional structures as well as to identify further sequences of similar homology. These approaches are most easily facilitated by storing the sequence in a

## DEFINITIONS

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as the case may be, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heine, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available computer programs. Computer program methods to determine identity between two sequences include, but are not limited to, the GAP program in the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN (Altschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 (1990), and FASTA( Pearson and Lipman *Proc. Natl. Acad. Sci. USA* 85: 2444-2448 (1988). The BLAST family of programs is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Parameters for polypeptide sequence comparison include the following:

Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)

Comparison matrix: BLOSSUM62 from Henikoff and Henikoff,

*Proc. Natl. Acad. Sci. USA.* 89:10915-10919 (1992)

Gap Penalty: 8

$$n_n \leq x_n - (x_n \bullet y),$$

wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides in SEQ ID NO:1,  $y$  is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and  $\bullet$  is the symbol for the multiplication operator, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ . Alterations of polynucleotide sequences encoding the polypeptides of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequences of SEQ ID NO:1, that is it may be 100% identical, or it may include up to a certain integer number of nucleic acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one nucleic acid deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleic acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleic acid alterations for a given percent identity is determined by multiplying the total number of nucleic acids in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleic acids in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \bullet y),$$

wherein  $n_n$  is the number of nucleic acid alterations,  $x_n$  is the total number of nucleic acids in SEQ ID NO:1,  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc.,  $\bullet$  is the symbol for the multiplication operator, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ .

reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \bullet y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2,  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and  $\bullet$  is the symbol for the multiplication operator, and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

"Individual(s)," when used herein with reference to an organism, means a multicellular eukaryote, including, but not limited to a metazoan, a mammal, an ovid, a bovid, a simian, a primate, and a human.

"Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

"Polynucleotide(s)" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA including single and double-stranded regions.

**EXAMPLES:**

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are illustrative, but do not limit the invention.

**Example 1: Cloning of the BASB231 gene from non typeable *Haemophilus influenzae* strain 3224A.**

Genomic DNA is extracted from the non typeable *Haemophilus influenzae* strain 3224A from  $10^{10}$  bacterial cells using the QIAGEN genomic DNA extraction kit (Qiagen GmbH). This material (1 $\mu$ g) is then submitted to Polymerase Chain Reaction DNA amplification using two specific primers. A DNA fragment is obtained, digested by the suitable restriction endonucleases and inserted into the compatible sites of the pET cloning/expression vector (Novagen) using standard molecular biology techniques (Molecular Cloning, a Laboratory Manual, Second Edition, Eds: Sambrook, Fritsch & Maniatis, Cold Spring Harbor press 1989). Recombinant pET-BASB231 is then submitted to DNA sequencing using the Big Dyes kit (Applied biosystems) and analyzed on a ABI 373/A DNA sequencer in the conditions described by the supplier.

**Example 2: Expression and purification of recombinant BASB231 protein in *Escherichia coli*.**

The construction of the pET-BASB231 cloning/expression vector is described in Example

1. This vector harbours the BASB231 gene isolated from the non typeable *Haemophilus influenzae* strain 3224A in fusion with a stretch of 6 Histidine residues, placed under the control of the strong bacteriophage T7 gene 10 promoter. For expression study, this vector is introduced into the *Escherichia coli* strain Novablue (DE3) (Novagen), in which, the gene for the T7 polymerase is placed under the control of the isopropyl-beta-D thiogalactoside (IPTG)-regulatable *lac* promoter. Liquid cultures (100 ml) of the Novablue (DE3) [pET-BASB231] *E. coli* recombinant strain are grown at 37°C under

B45292

calculated by 4-parameter logistic model using the XL Fit software. The antisera are also used as the first antibody to identify the protein in a western blot as described in example 5 below.

5 **Example 4: Immunological characterization: Surface exposure of BASB231**

Anti-BASB231 protein titres are determined by an ELISA using formalin-killed whole cells of non typable *Haemophilus influenzae* (NTHi). The titer is defined as mid-point titers calculated by 4-parameter logistic model using the XL Fit software.

10 **Example 5. Immunological Characterisation: Western Blot Analysis**

Several strains of NTHi, as well as clinical isolates, are grown on Chocolate agar plates for 24 hours at 36°C and 5% CO<sub>2</sub>. Several colonies are used to inoculate Brain Heart Infusion (BHI) broth supplemented by NAD and hemin, each at 10 µg/ml. Cultures are grown until the absorbance at 620nm is approximately 0.4 and cells are collected by  
15 centrifugation. Cells are then concentrated and solubilized in PAGE sample buffer. The solubilized cells are then resolved on 4-20% polyacrylamide gels and the separated proteins are electrophoretically transferred to PVDF membranes. The PVDF membranes are then pretreated with saturation buffer. All subsequent incubations are carried out using this pretreatment buffer.

20

PVDF membranes are incubated with preimmune serum or rabbit or mouse immune serum. PVDF membranes are then washed.

PVDF membranes are incubated with biotin-labeled sheep anti-rabbit or mouse Ig.

PVDF membranes are then washed 3 times with wash buffer, and incubated with

25

streptavidin-peroxydase. PVDF membranes are then washed 3 times with wash buffer and developed with 4-chloro-1-naphthol.

**Example 6: Immunological characterization: Bactericidal Activity**

Complement-mediated cytotoxic activity of anti-BASB231 antibodies is examined to

30

determine the vaccine potential of BASB231 protein antiserum that is prepared as

B45292

Mice are killed between 30 minutes and 24 hours after challenge and the lungs are removed aseptically and homogenized individually. The log<sub>10</sub> weighted mean number of CFU/lung is determined by counting the colonies grown on agar plates after plating of dilutions of the homogenate. The arithmetic mean of the log<sub>10</sub> weighted mean

5 number of CFU/lung and the standard deviations are calculated for each group.

• Results are analysed statistically.

In this experiment groups of mice are immunized either with BASB231 or with a killed whole cells (kwc) preparation of NTHi or sham immunized.

10

**Example 9: Inhibition of NTHi adhesion onto cells by anti-BASB231 antiserum.**

This assay measures the capacity of anti BASB231 sera to inhibit the adhesion of NTHi bacteria to epithelial cells. This activity could prevent colonization of the nasopharynx by NTHi.

15 One volume of bacteria is incubated on ice with one volume of pre-immune or anti-BASB231 immune serum dilution. This mixture is subsequently added in the wells of a 24 well plate containing a confluent cells culture that is washed once with culture medium to remove traces of antibiotic. The plate is centrifuged and incubated.

Each well is then gently washed. After the last wash, sodium glycocholate is added to  
20 the wells. After incubation, the cell layer is scraped and homogenised. Dilutions of the homogenate are plated on agar plates and incubated. The number of colonies on each plate is counted and the number of bacteria present in each well calculated.

25

## SEQUENCE INFORMATION

## BASB231 Polynucleotide and Polypeptide Sequences

## 5 SEQ ID NO:1 polynucleotide sequence of Orf1

GTGTGCTATGAGCCATTTATTTATTACCCAATGATGTGCAATGAAAAGATAGCGCGTGCTATTATTCTTG  
 AAGATGATGCGATTGTATCGCACGAATTCGAAGCAATTGTAAAAGACAGTTTGAAGAAAGTTTCAAAAAA  
 TGTTGAAATTTTATTTTATGATCATGGTAAAGCAAAAAGTTATTGCTGGAAAAAACACTTGTCAAAAAT  
 TACCGTTTAGTTCACTATCGTAAACCCTCTAAAAAGTCTAAACGTGCAATCATGTGTACAACAGCTTATT  
 10 TAATTACTTTTATCTGGCGCTCAAAAACCTCTACAAATAGCCTATCCTATCCGTATGCCTGCTGACTACTT  
 AACTGTGCTTTACAATTAAGTGGACTAAAGGCTTATGGTGTGAACCACCTTGTGTATTTAAAGGCGCA  
 ATTTTCAGAAATTGATGCAATGGAGCAACGCTAA

## SEQ ID NO:2 polypeptide sequence of Orf1

VCYEPFIYYPMMCNEKIARAIILEDDAIVSHEFEAIVKDSLKKVSKNVEILFYDHGKAKSYCWKKTIVKNYR  
 15 LVHYRKPSKTSKRAIMCTTAYLITLSGAQKLLQIAYPIRMPADYLTGALQLTGLKAYGVEPPCVFKGAISEI  
 DAMEQR.

## SEQ ID NO:3 polynucleotide sequence of Orf2

ATGAAATTAAAAATAAATTACAAATGTTAAGGTTGGGTCTAGGCAAATATTTCTTGATAAAAAAACG  
 GATTAAACAGAATAACAAATGTTCTTAGAAGCATCCTCTTCTCCGCAAGACGGAAAAATTGGGGATTA  
 20 TGTGGTGAGCTCATTTGTATTCCGTGAGATAAAAAATTTAATCCCCACATTAAAATTGGTGTAAATTTGT  
 ACCAAACAAAAATGCTTATCTTTTAAACAAAATCCATATATCGATCAACTTTACTATGTAAAAAGAAAA  
 GTATTTTGGATTACATCAAATGTGGTCTAGCAATTCAAAAAGAACAAATATGATTTAGTGATTGATCCGAC  
 GATTATGATTCGTAATCGCGATCTTTTACTTTTACGCTTAATCAATGCCAAGCATTATATTGGCTACCAA  
 AAAGCCAATTATGGTTTATTTAATATTAATCTGGAGGGACAATTTCACTTTTCGGAACCTCTATAAACTCG  
 25 CCTTAGAAAAAGTGAATATTACGGTACAAGATATAAGCTATGACATCCCATTTGATAAGCAAAGTGCGGT  
 CGAAATTTCTGAATTTTTCAGAAAAACCACTAGAAAAAGTATATTGCTATTAATTTTTATGGTGTGCA  
 AGAATCAAAAAGTAAACAATGACAACATCAAAAATATTTAGATTATCTCAGCAAGTCCGCGGAGGAA  
 AAAAGCTGGTGTATTAAAGCTATCCTGAAGTAACAGAGAAATTAACACAATTGTGAGCCGATTATCCGCA  
 TATTTTTGTCCATCCAACAACCAAGATCTTTCATACCATTGAATTGATTGCGCACTGTGATCAATTAATC  
 30 TCTACAGACACGTCTACTGTACATATTGCTTCAGGTTTAAATAAACCAATTATTGGTATTATATAAGAAG  
 ATCCTATTGCGTTTACACATTGGCAACCCAGAAGTCGGGCAGAAACGCACATACTTTTCTATAAAGAAAA  
 TATTAATGAGCTCTACCTGAACAAATTGACCCTGCATGGCTTGTCAAATAG

## SEQ ID NO:4 polypeptide sequence of Orf2

MKLKKNLQMLRLGLGKYFLDKKNGLNRIITNVPRIILFLRQDGKIGDYVVSSVFVREIKKFNPHIKIGVICTK  
 35 QNAYLQKQNPYIDQLYYVKKKSILDYIKCGLAIQKEQYDLVIDPTIMIRNRDLLLLRLINAKHYIGYQKANY  
 GLFNINLEGQFHFSELYKLALAEKVNITVQDISYDIPFDKQSAVEISEFLQKNQLEKYIAINFYGAARIKKVN  
 NDNIKKYLDYLTQVRGGKLVLLSYPEVTEKLTQLSADYPHIFVHPTTKIFHTIELIRHCDQLISTDTSTVH  
 IASGFNKPILIGIYKEDPIAFTHWQPRSRATHILFYKENINELSPQIDPAWLK.

## SEQ ID NO:5 polynucleotide sequence of Orf3

ATGCCAGAATTACCTGAAGTTGAAACCACAAAAAATGGAATTAGCCCTTATCTTGAAGGGGCTATCATTG  
 40 AAAAAATTGTTGTTTCGCCAACCGAAATTACGCTGGATGGTAAGCGAAGAATTAGCGCAAATTACACAACA

B45292

MNELSLDADKLLFGYDKPLYLPLTFQCKKGEVISVFGTNGKGTLLHSLAHVLPVMSGQIRQQGHIGFVPQ  
SFSSPDYPVLEIVLMGRASKIGAFNLPSKTDETVLQMLACLDILHLAERNINMLSGGQRQLVLIARALATE  
CQVLILDEPTAALDVYNQXRVLQLIRFLATEQKMTIIFSTHDPYHSLCVADNVLLLLLPNQWKYGIASQILT  
ESHLKQAYNVPIKYSMIEEQQVLVPIFTIQ.

5 **SEQ ID NO:11 polynucleotide sequence of Orf6**

ATGAAGTCTATGTTAGCAAATCAGCGAGGTTTTATAACATCGCTGATTTTTATCTTGTATTATCATCGTAT  
TGTTCACTTTAAATATTGGCACTTTTTCGTTATCAACCGGAAAAGTGATGTCCATTTTATCTAAGCCTTT  
TCTTTTCGCAACACGCGTCTTTTACACCTATGGAATACCATATTGTTTGGCATGTACGCTTACCACGCATC  
ATTATGGCATTTTTTTTTCAAGGGGGGATCTGAGCGATGAGTGGTGCAACACTACAGGGCGTTTTTCATAATC  
10 CCCTTGTTGATCCTCATATTATTGGTGTACATCAGGGGCAGTTTTTGGAGGCAGTTTAGCAATTTTATT  
AGGATTCCCATCTTATTTATTGATTCTATCCACATTTTCTTTTGGTTTATTGACATTATTCTTGATCTAT  
GTAACCACAATGTTTCATCGGAAAAGGCAATCGTATTGTATTAGTTTTAGCGGGTGTCAATTTAAGTGGTT  
TCTTTAGCACTCTAGTGAGCTTAATCCAATATTTAGCGGATGCAGAAGAAGTTCTGCCGAGCATTGTATT  
TTGGTTATTAGGAAGTTTTGCCACCACTAGTTGGGCAAACTAGCTATATTGTTACCCTGCGTTTTTATT  
15 GCAGCTTATTTATTATTCCGTTTACGGTGGCATATTAATGTGTTATCGCTAGGTGATATGCAAGCAAAAA  
TGTTAGGCGTTTCCATTAAGAAAATGCGTTGGTTTGTCTACTTTGTGCATTGCTTGTAGCAACACA  
AGTCGCTGTTAGTGGGAGTATTGGGTGGATAGGGCTTGTTATTCCTCATTGACACGTTTTTTTGTAGGA  
AGTGATCACCGTTATCTATTGCCCCCTCCTTTTTGATTGGTGGGATTTTCATGATTGTTATTGATACAC  
TTGCACGTACGTTAACTTCTGCAGAAATTCCTGTAGGTATTATCACCGCTCTTTTAGGAGCACCCATTTT  
20 TACCTTGCTCCTATTAAAACTTATCGAAAGAAGTCATTATGA

**SEQ ID NO:12 polypeptide sequence of Orf6**

MKSMLANQRGFITSLIFILFIIVLFTLNIGTFSLSLSTGKVMSILSKPFLSQHASFTPMYHIVWHVRLPRIIM  
AFFSGGIXAMSGATLQGVFHNPLVDPHIIGVTSGAVFGGSLAILLGFPYLLILSTFSFGLLTLFLIYVTM  
FIGKGNRIVLVLAGVILSGFFSTLVSLIQYLADAEVLPISIVFWLLGSFATTSWAKLAILLPCVFIAAYLLF  
25 RLRWHINVLSLGDMAKMLGVSIIKKMRWFVLLLCALLVATQVAVSGSIGWIGLVIPHLTRFFVGS DHRVLLP  
ASFLIGGIFMIVIDTLARTLTS AEIPVGIITALLGAPIFTLLLLLKYRKSL.

**SEQ ID NO:13 polynucleotide sequence of Orf7**

ATGATTCAACGCTACGTTAAAATAGTCAGTATTGCTTTTATTACTTTTCTTAGGTTCTATTAATAATGCGT  
TTGCAGCACGTGTTATTACTGATCAATTAGGACGAAAGGTCACATATCCAGATGAAGTTAATCGTGTGTTGT  
30 TGTCTGACAGCATCAGACTTTAAATCTCCTTGCCCAGCTTGATGCAAAGGAAAGTGTAGTCGGAGTGTTA  
TCAAGTTGGAAAAACAATTAGGGAAAACTATGCACCAAAAGAAATGATTGAGCAAATCGAACAGGCTG  
GTGTGCCTGTTGTAGCCATTTCTTTGCGTGAAGATAAAAAAGGTGAAGAAGGAAAAGTCAACCCAGAAAT  
GGAAGATGAAGAAGTTGCCTATAATAATGGTTTGAAACAAGGCATTTATTTAATTGGTGAAGTAATTAAT  
CGACAAGCGCAAGCCCAAAAGCTAGTTACTTACACTTTTGAACAGCGTGAATTAGTGAGTCAACGTTTAA  
35 GTAAGGTGCCTGATGAGCAGCGTGTAGGGTCTATATTGCAAATCCAGATTTAGCGACTTATGGTTCTGG  
AAAATATACAGGGTTAATGATGCTTCATGCTGGAGCGAAGAATGTGGCAGCTGAAACAATAAAAGGTTTT  
AAACAAGTTTCGATTGAGCAAGTGATTCAATTGGAATCCTGCAGTTATCTTCGTACAGGAACGTTATCCTC  
AGGTTATCGAGCAAATTAAAAAGGATCCCTCTTGCCAAATTATTGATGCGGTGAAAAATCAACGTATCTA  
TTTAATGCCGGAATATGCAAAAGCGTGGGGATATCCAATGCCTGAAGCATTAGCGATTGGTGAATTATGG  
40 TTAGCAAAACAACTTTACCCTGAATTGTTTGCAGATGTTGATTTAGAGGAAAAAGTAAACCAATACTATA  
AATTGTTCTATCGTATGCCATATAACCAAGTAA

**SEQ ID NO:14 polypeptide sequence of Orf7**

MIQRYVKIVSIALLLFLGSINNAFAARVITDQLGRKVTIPDEVNRVVVXQHQTLLNLLAQLDKESVVGVLSS  
WKKQLGKNYAPKEMIEQIEQAGVPVVAISLREDKKGEKGKVNPEMEDEEVAYNNGLKQGIYILIGEVINRQAO

B45292

AACGCCGGATTTTTAGCCCAAACCGAGCAAGAAATTACCGCTTGGTGCGAAGCGCAGGGCATAGCCTTAA  
ACAACAAAAACAAGACCAAGCTGCTGGACGTCAAAACCTGGGAAAAAGCCGCCGCACTTTTTTCAGACGGC  
ATCAACCTTGCTCGAACATTTTCGGCGAACAACAATTTGACGATTTCAACCAATTCAAACAAGCCGTGGAA  
TGCCGCTCTGAAAGCCGAAAAAATCCCCCTTTCTGCCACAGAGAAAAAGGCCGTTTTCAATGCCGTAAGTT  
5 GGTACGACGAAAATTCAAGCCAAAGTGATTGCCAAAACACTCAAGCTCAAACCAAACGAATTGGACGCCCT  
TTGCCAACGCTACCAATGCCAAGCCGACGAGCTGGCAGACTTTGGCTATTACGCCACCGGCAAAGCAGGC  
GAATATATCCTATATGAAACGAGCAGCGACTTGCGCGACAGCGAATCCATACCGCTCAAACAAAATATCC  
ACGACTATTTCAAAGCCGAAGTGCAAGCGCACATCAGCGAAGCATGGCTGAATATGGAAAGCGTAAAAAT  
CGGCTATGAAATCAGCTTCAACAAATCTTCTACCGCCACAAACCATTACGCAGCCTTGCGAAGTTGCCCA  
10 AGATATTTTGGCGTTAGAAAAACAGGCTGACGGCTTGATTAGTGAAATTCTAGAGGCTTAA

**SEQ ID NO:18 polypeptide sequence of Orf9**

MEHSVHNLKLVFSFIWSIADDCLRDVYVRGKYRDVILPMFVLRRLDTLLEPSKDAVLEEMRFQKEELAFTELDD  
LPLKKITGHVYNTSKWTLKSLYQTASNTPOYMLANFEEYLDGFSTNIHEIINCFLKREQIRHMSHKNVLLS  
15 VLEKFVSPYINLTPKEQQDPEGKLPALTNLGMGYVFEELIRKFNEENNEEAGEHFTPREVIELMTHLVFDP  
LKDQIPAIITIIDPACGSGGMLTESQNFIEQKYLSESGERSIFLFGKETNDETYAICKSDMMIKGDNPEN  
IKVGSTLATDSFQGNHDFMLSNPPYGKSWSKDQAYIKDGNEVIDSRFKVTLDPDYWGNVETLDATPRSSDGQ  
LLFLMEMVSKMKSPNDNKIGSRVASVHNGSSSLFTGDAGSGESNIRRHIEKDLLEAIVQLPNNLFYNTGITT  
YIWLLSNNKPEARKGKVLIDASLLFRKLRLKLNLDKNCFEVPEHIAEITQNYLDFTAKARETDSQNEAVGLA  
20 SQIFDNQDFGYKVTIERPDRRSAQFTAENISPLRFDKALFEPMQYLYRQYGEQIYNAGFLAQTEQEITAWC  
EAQGIALNNKNKTKLLDVKTWEKAAALFQTASTLLEHFGEQQFDDFNQFKQAVECRLKAEKIPLSATEKKAV  
FNAVSWYDENSARKVIAKTLKLPNELDALCQRYQCQADELADFGYYATGKAGEYILYETSSDLRDSSEIPLK  
QNIHDYFKAEVQAHISEAWLNMESVKIGYEISFNKYFYRHKPLRSLAEVAQDILALEKQADGLISEILEA.

**SEQ ID NO:19 polynucleotide sequence of Orf10**

ATGCAGCCGGAAAAACCAATATTTTGGACGCAAAGGACTAGGAGAAAAAGACATCAAGCCAACTAAAATAG  
25 CTGAAGAATTAGTTGGAATGCTCAATGCTGATGGCGGAGTTTTGGCTTTTGGTGTGGCAGATAATGGCGA  
AATCCAAGACTTGAATAGCCTTGCGGATAAATTAGATGATTATCGGAAATTGGTTTTTCGATTTTATTGCA  
CCGCCTTGTGGATTGGACTGGAAGAAATCTGGTTGATGGAAAATTAGTTTTCTTATTCACGTAGAGC  
AAGATTTAGAGCGTATTTATGTGCGCAAAGACAATGAAAATGTGTTCTTACGTGTAGCAGATAGTAATCG  
AGGCCCTCTCACCAGAGAACAAATCAAAAATCTTGAATATGATAAAAATATCCGTCTATTTGAAGATGAA  
30 ATAGTTCCTGATTTTAATGAAGAAGATTTAGATCAAGAATTATTAGAGCTATATAAAAAAGAAAGTTAATT  
TTACCTCCGATAATATCTTAGATTTATTATACAAGCGAAATTTATTAACCAAAAAGGAAGTTGTATCA  
GTTTAAAAAATCAGCCATTTTACTCTTTTCTACCATGCCGGAACGTTACATTCCTTCAGCATCAGTCCGC  
TATGTTTCGTTATGAAGGTACAGTAGCGAAAGTCGGTACTGAGCATAATGTGATAAAAAGACCAACGTTTTG  
AAAATAATATTCCAAAGCTAATTGAGGAGCTGACCTATTTTTTAAGAGCCTCTTTAAGGGATTATTACTT  
35 TCTTGATGTCAATCAGGGAAAATTTATCAAAGTACCGGAATATCCTGA

**SEQ ID NO:20 polypeptide sequence of Orf10**

MQPENQYFERKGLGEKDIKPTKIAEELVGMLNADGGVLAFGVADNGEIQDLNSLGDKLDDYRKLVFDFIAPP  
CRIGLEEILVDGKLVFLFHVEQDLERIYCRKDNENVFLRVADSNRGPLTREQIKNLEYDKNIRLFEDEIVPD  
40 FNEEDLDQELLELYKKKVNFTSDNILDLLYKRNLLTKKEGQYQFKKSAILLFSTMPERYIPSASVRYVRYEG  
TVAKVGTEHNVIKDQRFENNIPKLEELTYFLRASLRDYYFLDVNQKFIKVPEYP

**SEQ ID NO:21 polynucleotide sequence of Orf11**

ATGTCAATCAGGGAAAATTTATCAAAGTACCCGGAATATCCTGAAGAAGCTTGGTTAGAAGGTGTTGTAA  
ATGCGCTTTGTGCATCGTTCTTACAATGTTCAAGGTAATGTTATTTATATTAACATTTTCGACGATCGTCT  
45 TGAAATTAGTAATAGTGGCCCTCTCCCTGCTCAAGTCACCATTGAAAATATTTAAACGGAACGATTTCGCT

B45292

TTTTGATTTGCTCTACCCCGTTCCGCTTGCCAGCAGCGGCGAAAAGGTCAAGCAGCGTTTTGAACAGAAT  
TTGTTTAGCTGTATGCGTCAAGTGCCCTATTCTGCCTCAAGCAATGAAACGGTGGATATGGTGCTGTTTG  
CCAATGGCTTGCCGATTATTGCCCTTGAGCTGAAAAACCATTGGACAGGTGACAGCCATTGATGCGCA  
AAAACAATACCTCAACCGTGATTTAAGCCAAACGTTGTTCCATTTTCGGGCGTTGTTTGGCGCATTTTGCC  
5 TTAGATACGGAAGAAGCTTATATGACCACCAAATTGGCGGGGCTGCTACGTTTTTCTTGCCGTTTAACT  
TGGGCAACAACCTGCGGTAAGGGTAATCCGCCCAATCCCAATGGACACCGCACGGCGTATTTATGGCAAGA  
GGTGTTTCGGCAAAGCAAGCCTTGCCAACATTATTAGCATTATTTATGCGCTTAGACGGTTCAACCAAAGAT  
CCGTTGGATAAACGTACCCCTCTTTTCCCTCGCTATACCAATTAGATGTGGTCCGCCGTTTGATTGCTG  
ATGTCAAGTGAACATGGCGTGGGTAAACGTTATTTGATTCAACATTCTGCCGTTTCGGGCAAGTCTAATTC  
10 CATTACTTGGCTGGCGTATCAGTTGATTGAGGCATATCCGCGCAATGAAAGGCGGCAAACGGTAGAGAG  
GCAGACCGCCCGATTTTGTGATTGCGTGATTGTCGTAACCGACCGTCGTTTGTGGATAAGCAACTGCGCG  
ACAATATCAAAGATTTTTCAGAAGTTAAAAACATTGTTGCGCCGGCGTTGAGTTTCGGCAGAGTTGCGCCA  
ATCGCTTGAGCAGGGCAAAAAAATCATTATTACCACGATTCAAAAATTCCCGTTTATTGTGCGATGGCATT  
GCTGATTTAGGCGACAAACAATTTGCGGTGATTATTGATGAGGCACACAGCTCACAATCAGGTTTCGGCAC  
15 ACGACAATATGAACCGGGCCATCGGCAAAACGGAAGACCTTGATGCTGAAGATGTGCAAGATTTGATTTT  
ACAAACCATGCAATCCCGCAAAATGCACGGCAATGCGTCGTATTTTGCTTTCACCGCCACACCGAAAAAC  
AGCACTTTGGAAAAATTCGGCGAAAAACAGGCGGATGGCAAGTTTAAAGCCGTTCCACCTTTATTCTATGA  
AGCAGGCGATTGAAGAAGGCTTTATTTTGGATGTAATCGCCAATTACACCACCTATAAAAGTTTTTATGA  
GATCACTAAGTCGATTGAAGATAATCCGGAGTTTGATAGTAAAAAGGCTCAAAGCCGTCTGAAAGCCTAT  
20 GTGGAGCGTTCGCAACAAACGATTGATACTAAAGCGGAGATAATGCTGGATCATTTTATTTACCAAGTTT  
TCAACCGTAAAAAACTCAAAGGCAAAGCCAAGGGAATGGTGGTAACGCAAAATATTGAAACCGCCATCCG  
CTATTTTCAGGCGTTAAACATTTGCTGGCCGGGCGGGGTAATCCGTTTAAATTTGCGATTGCGTTTTCA  
GGCAGTAAAGTGGTTGACGGTGTGGAATACACCGAAGCGGAAATGAACGGCTTTGCAAGAAAGCGAAACCA  
AAGAGTATTTTCGATCAAGATGAATATCGTTTGCTGGTGGTGCAGCAATAAATATCTGACCGGTTTCGATCA  
25 GCCGAAATTGTGTGCCATGTATGTGGATAAGAACTCTCCGGCGTGCTTTGCGTGCAGGCTTTATCTCGT  
TTGAATCGCAGTGCGAATAAGTTGAGTAAACGCACGGAAGATTTGTTTGTATTGGACTTTTTTAACAGCG  
TTGAAGATATTCAGCAGGCATTTGAGCCGTTTTATACTTCTACTTCGTTGTGCGAGGCAACCGATGTCAA  
TGCTTTCGATGATTTGAAAGACCGGTTGGATGAAACCGGCGGTGTACGAACAAGCGGAGGTCAACGATTTT  
ACTGAAGGCTATTTTGCCAATAAAGACGCACAGCAATTAAGCAGTATGATTGATGTGGCTGTCCAACGTT  
30 TTGATGATGAATTGGAATTGGATTTGGATCGAAATGAAAAAGTTGATTTTAAATCAAGGCAAAACAGTT  
TTTAAAAATTTACGGGCAAATGGCCTCCATCATCAATTTTGAAAATATCGCTTGGGAAAAGCTCTATTGG  
TTCCTCAAATTCCTTAGTACCCAAATTAAAAGTACAAGACCCGATGGATGAATTTGATGAAATTTTAGATG  
CAGTGGATTTAAGCTCTTACGGCTTGGCGCACACCAAGCTGAATTACAGCATTAAATTAGATGATGAAGA  
AACAGAGCTTGACCCGCAAAACCCCAATCCGCGCGGTACGCATGGTGAAGATAAAGAAAAAGATCCGATT  
35 GATGAAATTATTTCGTGTATTTAACGAAAGATGGTTTCAAGATTGGAGCGCAACGCCGATGAGCAACGGG  
TAAATTTTATCAATATTACCGAGCGCATCCGCGAGCCATAAAGACTTTGAGCAGAAATATCAAAATAACCC  
GGATATTTCATACCCGTGAATTGGCTTTCCAAGCCATTTTGCAGCGATGTGATGAGCGAACGCCATAGGGAT  
GAATTAGAGCTATACAACTTTTTTGCCAAAGATGCCGCATTTAGAACCGCTTGGACGCAAAGTTTGCAAC  
GGGCTTTGGCTGGATAG

SEQ ID NO:26 polypeptide sequence of Orf13

MVSGTKEKDLEIAIEKALTGTWRENMENKLGEPKAEYLPRHHGFKLAFSQDFDAQFAIDTRLFWQFLQTSQE  
AELARFQQLNPNDWQRKILERLDRQIKNGVLHLLKKGLDIDSAHFDLLYPVPLASSGEKVKQRFQNLFS  
MRQVPYSASSNETVDMVLFANGLPIIALELKNHWTGQTAIDAQKQYLNRLDSQTLFHFGRCLAHFALDTEEA

B45292

MSEYKLNPPPTVSSY TENMMLKVLF EHKGFSEV FRETSWRSDEIASAFGLPEELEN DKNLRTVARRLLKERYK  
KLQKSTALLPELWKQAYENLATLAEFLQ LNPVEQELLRFAMHLRSEGAMRDLFGYLPKSDLQRTAAIMADLL  
KQPKNQILSALKKGSKL DAYGLIDRDYRPSVHDYLDWGETLDFDEFVTQPLNENVLLKSCTEVAQVPSLQL  
DDFDHIAGMKEMMLTYLQQALKHHRKGVNLLIYGVPGTGKTEFAGLLAQALGISAYNITYMDSGDVVEAEQ  
5 RLNYSRLAQ TLLNGKQALLIFDEIEDVFNGSFMERSVAQKNKAWTNQ LLENNVPMIWLNSVSGIDPAFLR  
RFDFILEMPDLPLKNKSALITQLTEGKLSPAYVQHFAKVRSLTPAILSR TIRVAKELNTSNFAETLLMMFNQ  
TLKSQNKPKIEPLVLGKADYNLDYVACNDNIHRISEGLKRSKKGRICCYGPPGTGKTAWAAWLAEQLDMPLL  
LRQGSDDLNPYVGGTEQNIQAFAEQAKADNAILVLDEVDTFLFSREGANRSWERSQVNEMLTQIERFEGLMV  
10 VSTNLIEVL DHAALRRFDLKLKFDYLT LKQRLDFAKQQA EILGLPLLSEEDLSQIESLNLITPGDFAAVARR  
HQFSFPHKVQDWLMA LQGECEVKPAFSATTRRIGF.

**SEQ ID NO:29 polynucleotide sequence of Orf15**

ATGTTTGAAAAAATTGAACCTACTAATATTCGTTTTATTAAATTAGGCATAAAAGGATGTTGGGAAAAAG  
ATTGTATTGATAAAAATAGTACAGCAAGTACAAAAAATACGATTCGTCTTGCTATGAATCTACATCAGA  
GATTCACAAAGAATGTTTGAATAATCAATGGGATAGTTGTATTGAATATTGTA AAACCTATTGGAGTGAC  
15 CATACAGGAAC TGTTC AAATCACTTGAGACAAATTC AAGATTTTTATCAACTTGGGGAAGATACACTTT  
GGATCACCTTCTTTGGACGTAAATTATATTGGGCTTTTTG CAGTAAAGAGGTGTTGAGGAAAGCGATGG  
TTCTAGAACAAGAAAAGTTATTAGTAACAATGGGAATTGGTCTTGCGTTGATGCTAACGGTAAAGAGCTT  
TTAGTCGATAATCTTGATGGTAGAGTAACAAAGGTCCAAGCCTATAGAGGGACGATTTGTGGTGTGAGA  
TGGAGGACTATTTAATACGTCGTATAAATGGTGAAGTTATTGAGGAAATTACAGAAGCGAAAGAGGCGTA  
20 TGAAACATTAATTAAATCAGTTGAAAAATTAATTAAAGGTTTATGGTGGAGTGACTTTGAAC TTTTAACG  
GATCTTGTTTTTTCTAAATTAGGATGGCAACGATACTCTGTTTTAGGTAAAACGGAGAAAGGAATAGATC  
TTGATTTGTATTTCGTCTTCAACGCAGAAAGAGAGTATTTGTGCAAATTAAGTCAGATACGGATATTAAACA  
ATTAGACGAATATGTTTTCGAAC TTTGAAAGTGAATATAAAAAC TATGGTTATTTCAGAAATGTATTACGTA  
TATCATTCTGGTTTAGAAAACATAGATGAAAAACAATATCAAGCTAAAGGAATTAAGCTTGTAATGGCC  
25 GAAAAATGGCAGAGCTTGTAATTAGTGTGTTGTTAGTTGAATGGTTGATTAAACAAACGTTCTTAA

**SEQ ID NO:30 polypeptide sequence of Orf15**

MFEKIEPTNIRFIKLGKGCWEKDCIDKNSTASTKNTIRLG YESTSEIHKECLNNQWDSCIEYCKTYWSDHT  
GTVSNHLRQIQDFYQLGEDTLWITFFGRKLYWAFCSKEVVEESDGSRTKVISNNGNWS CVDANGKELLVDN  
30 LDGRVTKVQAYRG TICGVEMEDYLIRRINGEVIEEITEAKEAYETLIKSV EKLKGLWWSDFELLTDLVFSK  
LGWQRYSVLGKTEKGIDLDLYSSSTQKR VVFIKSDTIKQLDEYVS NFESYKNGYGYSEMYVYHSGLENI  
DEKQYQAKGIKLVNGRKMAELVISAGLVEWLINKRS.

**SEQ ID NO:31 polynucleotide sequence of Orf16**

TTACCCCTTTGCCAACAAAATTGGCAGCAACAAGCGACGCAACCAAGATGCCCTTTTTTAATGGCGAGGCGG  
TGTTTTCAATATAAACTCAAAACGGCTGAAAAACGCCTTGAAAAACCGACCGCACTTTATTGTGGGCGTGGC  
35 AGATGGTATTTCTAATAGCAACCGACCTGAAAAAGCGAGCAAATTTGGCTATGCAATTATTAAGCCAAATG  
GAAAGTATAAACCGTCAAACGATCTACGATTTACAATCCAGTTTATCAGCAGAATTAGCTGAGGATTATTT  
TTGGTTTCGGCGACCACATTTGTGGCTGCCGAAATTGATCAAATAACCCGTAAAGCGAAAATTCTCAGCGT  
AGGCGATAGTCGTGCTTATTTAATTGATGCCCAAGGAAAATGGCAACAAATCACCCAAGATCATTTCTATT  
CTTTCTGAATTATTGACTGATTTCCCCGATAAAAAAGAGAAGATTTTGCCACGATTTATGGCGGCGTTT  
40 CTTCTTGTTTTAGTCGCCGATTATTCGAATTTCAAGATAAAATTTTTTATCAAGAAATTGAAATTCAGCA  
AGGGGAAAGTTTATTACTTTGTTCTGACGGCTTGACCGACGGGCTTTCAGATGAAATGCGCGAAAAAATT  
TGGCAGAAATATCCCGATGATAAATATCGCCTTACGGTTTGCCGCAAGATGATTGAGAAGCAATCGTTTT  
CGGATGATTTGTGGTAGTTTGTGTGTCATTCTATTATTGAGTAA

**SEQ ID NO:32 polypeptide sequence of Orf16**

LPFANKIGSNKRRNQDALFNGEAVFQYKLKTA EKRLNRPHFIVGVADGISNSNRPEKASKLAMQLLSQMES  
45 INRQTIYDLQSSLSAELAEDYFGSATTFVAAEIDQITRKAKILSVGDSRAYLIDAQ GKWQQITQDHSILSEL

B45292

TCAATGATACTGGGCTTGCCGCGCTCACTTTATTAGTTGCTGAATCTGATCCGAAACAAAAGAAACGCT  
TATTAGGCTTATTATGCATATGCTTAAGCAAGAGAAAAATGA

**SEQ ID NO:38 polypeptide sequence of Orf19**

MLVIKENNMNNQNPIEIIYQTDGTTQVEVRFENDTVWLSQAQMAMLFKDIRTINEHITNIFDDEELEKE  
5 STIRKFRIVRQEGKRQVNREIEHYDLDMIISVGYRVKSKQGISFRRWATARLKEYLTQGYTINQKRLQQN  
AHELEQALALIQKTANSSELTLESGRGLVDIVSRYTHTFLWLQQYDEGLLAEPQTQGGTLPITYAEAFSA  
LAELKSQMLTKGEASDLFGRERDNLSSAILGNLDQSVFGEPAYPSIEAKAAHLLYFVVKNHFFSDGNKRS  
GAFLFVDFLHRNGLFDHNGYPVINDTGLAALTLLVAESDPKQKETLIRLIMHMLKQEKK.

**SEQ ID NO:39 polynucleotide sequence of Orf20**

10 ATGACAGAGAAAAATAAACCAATTTGCGTGGTATTAACGGGAGCTGGCATTAGTGCCGAAAGTGGAATTC  
CAACTTTTAGATCGGAAGATGGTTTGTGGGCAGGGCATAAAGTAGAAGAAGTTTGTACGCCCGAAGCCTT  
GCAAAAGAACCGTGCGAAAGTGCTTGATTTCTATAACCAACGCCGTAAAAATGCGGCAGCAGCTAAGCCA  
AACGCTGCGCATCTCGCCTTAGTTGAACTAGAAAAAGCCTATGATGTGAGAATCATCACGCAAAATGTGG  
ATGATTTACATGAACGTGCCGGCAGCTCGAAGGTGTTGCATTTACACGGTGAATTAATAAAGCTCGCAG  
15 TAGCTTTGATGAAAGTTATATTGTGGATTGTTTTGGTGATCAGAAATTAGAAGATAAAGATCCAAATGGA  
CACCCAATGCGCCCTTACATCGTCTTTTTTGGTGAAATGGTGCCGATGCTAGAACGAGCGGTTGATATTG  
TGGAACAAGCAGATGTTGTGTTAGTGATTGGCACTTCTTTACAAGTGATCCAGCCAATGGCTTAGTCAA  
TGAAGCCCCAAGAAAAGCGCCAATTTATCTGATTGATCCTAACCCAAATACAGGATTTGTTCTGAAGCAA  
GTTATTGCAATCAAAGAAAAGCAGGCGAGGGTGTGCCAAAAGTGGTGGCAGAGTTATTAGAGAACACCA  
20 AAAACTCATAG

**SEQ ID NO:40 polypeptide sequence of Orf20**

MTEKNKPICVVLTGAGISAESGIPTFRSEDGLWAGHKVEEVCTPEALQKNRAKVLDIFYNQRRKNAAAAKP  
NAAHLALVELEKAYDVRIITQNVDDLHERAGSSKVLHLHGEELNKARSSFDESIVDCFGDQKLEDKDPNG  
HPMRPYIVFFGEMVPLERAVIDVEQADVVLVIGTSLQVYPANGLVNEAPRKAPIYLIDPNPNTGFVRKQ  
25 VIAIKEKAGEGVPKVVAELLENKNS.

**SEQ ID NO:41 polynucleotide sequence of Orf21**

ATGAAGAAAATTGTTTATATTGATATGGATAATGTGATGGTAGATTTTCCATCAGGTATTGCAAACTAG  
ATGATAAAACCAAGCGAGAATATGAAGGTCGATATGATGAAGTCGAGGGCATTTTTAGCTTAATGGAACC  
TATGCCGAATGCGATTTCTGCGGTGCATAAATTGATGAAAAAATATCATATTTATGTGCTTTCTACTGCG  
30 CCTTGGCATAATCCTTTTGCTTGGAGTATAAAAGTAAAATGGATTACCATTTATTTTCGGTGAAAGAAAAG  
GTTTCAGCCTTATATAAACGATTGATTTTATCCCATCATAAAAATCTCAACCAAGGTGATTATTTAATTGA  
TGATCGCACTAAAAATGGTGTCTGGCAAATTTCAAGGCGAGCATGTTTATTTTGGTACAGAACAGTTTGCT  
AATAAAAGGAGCCTGAAAAATGACAGAGAAAAATAA

**SEQ ID NO:42 polypeptide sequence of Orf21**

35 MKKIVYIDMDNVMVDFPSGIAKLDDKTKREYEGRYDEVEGIFSLMEPMNPNAISAVHKLMKKYHIYVLSTA  
PWHNPFAWSIKVKWIHHYFGEEKGSALYKRLILSHHKNLNQGDYLIIDRRTKNGAGKFQGEHVHFGTEQFA  
NKRSCLKNDREK.

**SEQ ID NO:43 polynucleotide sequence of Orf22**

40 CATTATCGGAGTATTCACGGTAAAGAACATAAGGCACAGGTCAAGCCCTTGGCTTTGGTTCAACAAGGAC  
CAAGTAGCTATTTAGTCGCACAATATGAGAATGGCGATATTTTACACCTTGCTTTGCATCGCTTGCTTAA

B45292

AATGAGCGTTTCGAGCTCCTGTTGGGGACATTAATATAGCACTTGAAAAATGCTGTATTGGTCGCGGATTA  
GCTGCATTACAACATAAGAGTAAAAGTTTGTCTGTTTCGGTTTATATCAAATACAATCTATAAAACCAGAAT  
TAGATTTATTTAATGGTGAAGGAACGTTTTTTGGTTCCTATCAATCAGGATAACTTAAAAAATATCCAAAT  
TATTAACCTGTATGAAAAATTTATTCAGCTTTTTTGAAAAATATTTATCATCTTGTGATTCAAAAATTATG  
5 AATAACGAGATAGAAAAATAATGCACCTGAAAGAAATAAGGGATTTATTGTTACCTAGATTATTGAGTGGAG  
AAATTCAATTATGA

**SEQ ID NO:48 polypeptide sequence of Orf24**

MNDWKVITLADCASFOEGYVNP SKNEPSYFGGTIKWLRATDLNNGFVYKTSQTLTEKGFLSAKKSAVLFEPD  
10 SLAISKSGTIGRIGILKDYMCNRAVINIKVNENICNPLFI FYTLLNSKEQIETLAEGSVQKNLYVSALSKV  
KLLLLLDINKQKEIGYIILNTLDQKIELNTQINQTLLEQIAQALFKSWFVDFDPVRAKIQALSDGLSLEQAEALAA  
MQAISGKTPEELTALSQTQPDRYAELAETAKAFPCMEVEVDGVEVPKGWELSTIGDCYDVVMGQSPKGETYN  
ENKQGM LFYQGRAEFGWRFP TPRLF TTDPKRIAEQNSILMSVRAPVGDINIALEKCCIGRGLAALQHKSKSL  
SFGLYQIQSIKPELDL FNGEGTVFGSINQDNLKNIQI INPDEKFIQLFEKYLSSCD SKIMNNEIENNALKEI  
RDLLLLPRLLSGEIQL.

**SEQ ID NO:49 polynucleotide sequence of Orf25**

ATGGAATTAATAAGCGATAATCCAATAAAAGATTCTAGCAATGATTTATTAGGTAGAGCTAGTAGTGCAG  
AAGCATTGCTAAACACATTTTTTCATTTGACTATAAAGAAGGTTTGGTTGTGGGATTATGTGGAGAATG  
GGGAAATGGTAAACATCCTATATAAATTTAATGCGACCAGAATTAGAAAAAATTCTTTTGTACTTGAT  
TTTAATCCTTGGATGTTTAGTGATGCTCATAACTTAGTTGCTTTATTTTTTACTGAAATCTCTGCTCAGT  
20 TAAGAGATTATGAGGATGATAATGAGCTAATTGATAGTTTGGAGAGTTGTTATCTAATTT  
AAAACCTATTCCATTTGTAGGAAATTATTTTAGTGCTTGGGTGGCTGTTTAAGTTTTTTTTCAAAGAAA  
AAGAAAGAAAAAACAGTTTGAAAAATCAACGTGATAAATTAATTAAAGTTCTAAAGGAAATAAGTAAAC  
CTATTACTGTAATTTTAGATGATATAGACCGTTTATCATCTGATGAATTACAATCAATTCTAAAATTGGT  
CAGAGTTACAGGAACTTTCTAATATTGTTTATGTTTATCATTTGATAAAAATAGAGTAATTAAACCA  
25 TTAAATGATAATACCATTGATGGCCAGGATTATTTAGAGAAGATAATTCAGATTCCATTCGATATACCAC  
AGGTACCTAAAAAACTATTACAAGAAAATTTATTTTCATCTTTAGATAAGATTTTAAGGGATGTTTACCT  
AGATAAGGCGCGTTGGTCTAATGCATATTGGAATATCATTAAGCCAACAATAAAAAATATTCGAGATATT  
AAGCGTTACACATCTTCTCTATCGAATATCTTTAAACAATTAGGTAAAGAAAATTGATGTGGTTGATTTAC  
TCACTATTGAAGCGATAAGAATTTTCTTTCCAGATAAATTTAAAGAAAATTTTGAACCTAAAGATTATCT  
30 CTTGGCACGATCAGATAATGACAAAAGAAAAGTTAAGTTAAGTGATTTTATTCAAGATAATGAAATGTAT  
GAGTCTTTTCTAGAAGTTTTATTTGATATTGATAATATAAATTCAAATAATGAATTCCTAAAAAATAGAA  
GGATTGCTTATTCGGCATTCTTTGATTTATATTTTGAACAAGTTATGAGTCCTGAGTTCATAAATGTTAA  
ATTATCACAAAAGTTTGGCTTGCAATGCAGTCAGAAGAAGATTTCAAGATCGCTTTATCAGCTGTTTCT  
GACGATTCTCTAGAAAATGTAGTTAACAATTTAATTGACTATGAAAAAGACTTTACTAAAGAAATAGCTC  
35 TAGCAACTATACCAACATTATATAGAAATTTACCAAGAGTGCCTGAAAAAGAATTAGGATTCTTTGACTT  
TGGGGCGGATATGGTTTGGAGTCGCTTAGTTTATAGATTACTTAGAAGACTTCCTGAGAAGGATAAAAAA  
GAAGTTATTACTCAACTATTAAATCTAGCGATCTATATGGGCAATATCAAATTGTAGGAATTATTGGAT  
ATCGAGAGGGCCGAGGTCAATTAGTATCTGAATCGGATGCAAAGACTTGGAGGAAATATTTTTTAA  
TAATATTCGCTCTGCAACAATTAAAGAAGCTTGCAGGAACCTATAATTTGTACATATAATCTATTTCTTT  
40 GTTTCAATTGGAAACCTTTTTCTGATGATATATTAAGTTCCCTGAAGTATTTTTATCATTACTTAAAT  
CTTCAATATCAGAACGTAAATCTCAAAGAGGGGATGATCCTACAATACATAGAGAGAAAATTCTACTTTG  
GGATGCCTTAATTAATAATTTGTGGAGATGAGGATAAAGTAAATAGTTTAATTGAAAAAATAGCTGAAGAT  
GAAGAACTTAGAAATAAAGATTATATGGAACCTGCAATTAATATAAGAATGGATACCGACATAAAAAAT  
CAATGAATCATGAAGATGATTTAGATGAGTTTAA

B45292

CGCGAAATTCGAGCCAGTGAATTGCGGTTTTATCAAAAAGTACGAGAGTTATTTAAATTATCCAGTGACT  
ACGATAAAACAGATAAAAGTCACTCAAATGTTTTTGCAGAAACACAAAATAAGTTGATTTATGCCATTAC  
ACAACAAACCGCCGAGAGCTTATTTGTACGCGTGCAAATGCCAAATTGCCTAATATGGGTCTTACCTCT  
TGGAAAGGTGCTGTTGTACGTAAAGGCGATATTATTACCGCTAAAAACTATTTAACTCATGATGAATTAG  
5 ATTCTTTGAATCGTTTAGTGATGATCTTTTTAGAAAGTGCTGAATTACGCGTTAAAAATCGTCAAGATCT  
CACATTAAATTTCTGGCGTAATAATGTCGATAATTTAATTGAATTTAACGGTTTTCCGTTGCTTATCGGT  
AATGGAACCCGAACCGTAAAACAAATGGAAACCTTTACCAAAGAACAATATGCCTTATTTGATCAGGTCA  
GAAAAACAACAAAAACGCATACAAGCTGATAATGAAGATTTAGAAATTTAGAAAACCTGGCAGAAAGATCT  
GAAAAAGCAAAAGCATTAA

**SEQ ID NO:54 polypeptide sequence of Orf27**

MNDLIYNTDDGKSHVALLVIENEAWLTQNQLAELFDTSVPNITTHIKNILQDKELDEFVSVIKDYLITAQ  
DSKQYQVKHYSIDMILAIGFRVRSRPGVQFRRWANTQLRTYLDKGFLDKERLKNPQGRFDHFDELLEQI  
REIRASELRFYQKVRELFKLSSDYDKTDKVTQMFFAETQNKLIYAITQQTAAELICTRANAKLPNMGLTS  
WKGAVVRKGDIIITAKNYLTHDELDSLNLRLVMI FLES AELRVKNRQDLTLNFWRNNDNLIEFNGFPLLIG  
15 NGTRTVKQMETFTKEQYALFDQVRKQKRIQADNEDLEILENWQKDLKKQKH

**SEQ ID NO:55 polynucleotide sequence of Orf28**

ATGCAACAGCGTGCTACTTTTTTTAAAAGCGTGGCTAAGCCAACGTTATACTAAAACCTGAACTGTGTCAGC  
AGTTTAAATATTAGCCGTCCAACGGCAGATAAATGGATTAAACGCCACGAACAGCTTGGTTTTGAGGGCTT  
20 AAGCGAGTTATCTCGTAAATCTTATCATAGCCCTAATGCCACGCCACAATGGATTGTGACTGGCTTATC  
AGTGAGAAACTTAAACGTCCTCACTGGGGTGCCAAAAGCTTTTAGATAACTTTACTCGGCATTTTCCAG  
AAGCGAAAAAGCCGTCTGATAGCACGGGCGATTTAATTTTGGCGTGTGCAGGGTTAAAACGTCGTATGAG  
TGCAGACACACAATCTTTTGGCGAATGCATCGCACCCAATACCACCTGGAGTGCTGACTTCAAGGGGCAA  
TTTTTACTCGGCAATCAGAAGTTCTGCTATCCGCTGACGATTACAGATAATTTAGCTCGCTTTTTATTTT  
25 GTTGTAAAGGGGTTGCCGAATACAAAATCAGCGCCTGTTATTGCTGAGTTTGAACGTCTTTTGTAGCAATT  
TGGTCTGCCGTATTTCGATTTCGTACCGATAACGATTCATCTTTTGCATCACAAGCATTAGGTGGATCTAGG  
TGTATTGACTTAGGTATTCTTCTGAACGAATTAAGCCATCACACCCAGAGCAGAACCGACGACACGAGC  
GAATGCACCGTAGCTTAAAAACAGCGCTTCAACCTCAAATAGCTTTGAAGCTCAACAGACATTCTTCAA  
CCAATTCTTACGAGAATACAAAGAAGAAATGTTACACGAAGGCGTTTGA

**SEQ ID NO:56 polypeptide sequence of Orf28**

MQQRVFLFKAWLSQRYTKTELCOQFNISRPTADKWIKRHEQLGFEGLSLSRKS YHSPNATPQWICDWLI  
SEKLKRPHWGAKKLLDNFTRHFPEAKKPSDSTGDLILACAGLKRMSADTQSFGEICAPNTTWSADFKGQ  
FLLGNQKFCYPLTITDNFSRFLFCCKGLPNTKSAPVIAEFERLFEQFGLPYSIRTDNDSSFASQALGGSR  
CIDLGIPSERIKPSHPEQNGRHERMHRSLKTALQPQNSFEAQQTFFNQFLREYKEEC SHEGV .

**SEQ ID NO:57 polynucleotide sequence of Orf29**

TGCCAAACGGCGAACAAATCCGCAGAAATTAAGCAGCGTTGTGGCTATTCTCGCTTCATGTTTAAATCGGGT  
TAACTTGGCAGAATGAACAATATAAGCAAGATAATGGCGTCAAGTTTCACTTATACGAAAATCGCCAAATT  
GCACCACAAAGTCACCAATACCCACAAAAAACTACTTGCATCAAATCCACACCGAATCAGCAAAAAC  
CACGCAATGATTTATATTGAGAGTTTGCAAGCAACAAATTACCAAGGAGATGCGGAAAATACAGTAAAAC  
GCGAAACAAAAATCAGACTTAAACCGTTCAACTTCAGCACAAATCTTGGCATGA

**SEQ ID NO:58 polypeptide sequence of Orf29**

CQTANKSAELSSVVAILASCLIGLTWQNEQYKQDNGVKFSYTKIAKLHHKVTNTHKKNYLHQIPHRISK  
HAMIIYESLQATNYQGAENTVKRETKIRLKPFFNFSTILA

**SEQ ID NO:59 polynucleotide sequence of Orf30**

B45292

TACTTTCCCCTGCTGGTGTAGCACAAATTACAACACATTGATATTAGTGAAGTGCCTGCCGCATTCAAAAA  
AATCAATAACCAATTTATTGGGATTTTAATTGGTGTGATTTTCAAGCTGAACCTTTACAACCGTTTCTATCAA  
GTTGAATTACCAAAGGCACCTTCGTTCTTTAGCGGAAAACGCCCTCGTCCCAATTTTGGTTTCTTTCGTGA  
TGATCGCCGTATCATTTGCCTTACTCTATATTTGGCCTCATATTTTAAACGCTCTCGTTTCATTTGGTGA  
5 ATCCATCAAAGATTTAGGTGCAGTAGGTGCGGGGATCTACGGTTTCTTCAACCGCTTATTAATTCCTGTA  
GGCTTACACCATGCCTTAAACTCTGTATTCTGGTTTGTATGTAGCGGGTATCAACGATATTCCAAACTTCT  
TGGGCGGCGCTAAATCCATTGCCGAAGGCACCTGCAACCGTGGGGCTAACTGGTATGTATCAAGCTGGTTT  
CTTCCCTGTGATGATGTTTGGTTTACCAGGTGCTGCTCTTGCAATTTATCACTGCGCAAAACCAAACCAA  
AAAGTACAAGTGGCCTCAATTATGCTTGCGGGTGCCTTAGCCTCTTTCTTTACAGGGATCACTGAACCGC  
10 TTGAATTCTCATTTATGTTTCGTTGCACCTGTACTTTATGTATTGCATGCATTATTAACAGGTATCTCTGT  
ATTCATTGCAGCTACAATGCACTGGATTGCAGGATTCCGATTTAGTGCAGGTTTAGTGGATATGGTACTT  
TCTAGCCGTAACCCACTTGCCGTTAGCTGGTATATGTTACTTGTACAAGGTATTGTATCTTTTGCTATCT  
ATTATTTTGTGTTCCGTTTGTCAATTAATGCCTTTAATCTCAAAACGCTAGGACGTGAAGATAAAGCGGA  
AACAGCTGCAGCCCCAACTCAAAGCGACCAATCTCGCGAAGAAAGAGCGGTGAAATTTATTGCTGCTTTA  
15 GGTGGTTCAGAAAACCTTCAAACCTGTGGATGCTTGTATCACTCGTTTACGCTTAACTTTAGTTGATCATC  
ACAATATTAACGAAGATCAACTTAAAGCGCTTGGTTCAAAGGTAATGTAAATTAGGCAATGATGGATT  
ACAAGTCATTTTAGGGCCTGAAGCTGAAGTTGTGGCAGATGCGATTAAAGCAGAATTAAATAA

**SEQ ID NO:66 polypeptide sequence of Orf33**

MSVLSYAQKIGQALMVPVAALPAAALLMIGYWIDPDGWGANSQLAALLIKSGAAIIDNMGLLFAVGVA  
20 GLAKDKHGSAAALSGLVGFYVVTLLSPAGVAQLQHIDISEVPAAFKKINNQFIGILIGVISAELYNRFYQ  
VELPKALSFSGKRLVPILVSFVMIASFALLYIWPFIHFNALVSFGESIKDLGAVGAGIYGFFNRLLIPV  
GLHHALNSVFWFDVAGINDIPNFLGGAKSIAEGTATVGLTGMVQAGFFPVMFGLPGAALAIYHCAKPNQ  
KVQVASIMLAGALASFFTGITEPLEFSFMFVAPVLYVLHALLTGISVFIAATMHWIAGFGFSAGLVDML  
SSRNPLAVSWYMLLVQGIVFFAIYYFVFRFAINAFNLKTLGREDKAETAAPTQSDQSREERAVKFIAAL  
25 GGSSENFKTVDACITRLRLTLVDHNNINEDQLKALGSKGNVKLGNDGLQVILGPEAELVADAIIKAEIK

**SEQ ID NO:67 polynucleotide sequence of Orf34**

ATGAAAACAACTTCTGAAGAATTAACGGTATTTGTGCAAGTAGTCGAAAATGGCAGTTTCAGCCGTGCAG  
CCAAGCAGCTATCAATGGCAAATCTGCGGTAAGTCGTGTGGTGAAAAGGCTAGAAGAAAAATTGGGTGT  
GAACCTAATCAACCGCACTACTAGACAGCTTAGACTAACAGAAGAAGGCTTACAATATTTTCGTGCGGTA  
30 CAGAAAATTCTGCAAGATATGGCTGCAGCTGAAGCTGAAATGTTGGCAGTGCACGAAGTCCACAGGCA  
TACTACGCGTAGATTACGCCATGCCGATGGTGTACATCTGCTAGTGCCACTGGCAGCAAAATTCACGA  
ACGCTATCCGCATATCCAACCTTCGTTAGTTTCTTCTGAAGGCTATATCAATCTGATAGAACGCAAAGTC  
GATATTGCCTTACGAGCTGGAGAATTGGATGATTCTGGGCTGCGTGCTCGTCATCTATTTGATAGCCACT  
TCCGCGTAATCGCCAGTCCAGACTACTTGGCAAACACGGCACGCCACAATCAACTGAAGCTCTTGCCAA  
35 CCATCAATGTTTAGGCTTCACTGAGCCCAGTTCACTAAATACATGGGAAGTTTTAGATGCTCAAGGAAAT  
CCCTATAAAATCTCACCGTACTTTACCGCCAGCAGCGGTGAAATTTTACGGTCATTGTGTCTTTCAGGCT  
GTGGTATTGCTTGCTTATCAGATTTTTTGGTAGACAATGACATCGCTGAAGGAAAAATTAATCCCTTACT  
TACTGAACAAACCGCCAATAAAACGCTCCCCTTCAATGCTGTTTACTACAGCGATAAAGCAGTCAACCTT  
CGCCTACGTGTGTTTTTAGACTTTTTAGTAGAAGAGCTAAGGGGATAA

**SEQ ID NO:68 polypeptide sequence of Orf34**

MKTTSEELTVFVQVVENGSFSRAAKQLSMANSAVSRVVKRLEEKLGVNLIINRTTQRLRLTEEGLQYFRRV  
QKILQDMAAAEAEMLAHVPEPQGILRVDSAMPVHLHLLVPLAAKFNERYPHIQLSLVSSEGYINLIERKV

B45292

GATGAACCCCTCAATTGAAAATAGAGGACAATTATACATGTGGATGAGAGAAGTAATATCTATAACTCACC  
CCAAATTATTCATAGCTGAAAATGTAAAAGGATTAACGAACCTTAAAGATGTAAAAGAAATTATTGAACA  
TGATTTTGGTCAAGCTAGTGACGAAGGATACTTAATTGTACCAGCTTCAGTATTAAATGCTCAGTTTTAT  
GGAGCTCCTCAATCACGTGAGCGTGTCAATTTTTTTTTTGGTTTTAA

5 **SEQ ID NO:74 polypeptide sequence of Orf37**

MKLISLFSGCGGMDIGFEGNFSCLKKSINEELHPEWISSTENEWTVSPTSFETIFANDIKPDAKAAWVS  
YFLDQKANANEIYHLESIVDLVKKERETHNIFPKGIDILTGGFPCQDFSVAGKRLGFD SHKNHHGKISNI  
DEPSIENRGQLYMMWREVISITHPKLFIAENVKGLTNLKDVKELIEHDFGQASDEGYLIVPASVLNAQFY  
GAPQSRERVIFWF

10 **SEQ ID NO:75 polynucleotide sequence comprising orfs1, 2, 3, 4, 5, 6, 7, 8 and non-coding flanking regions of these polynucleotide sequences.**

TATTGCAAACACTTCTCAGATGATTAAATAACATGGATACACGTTTGCCACACGGATTGCTGGTAACCTTT  
GACAGTCGATGAAATAGGTGTGCTATGAGCCATTTATTTATTACCCAATGATGTGCAATGAAAAGTAGCGC  
GTGCTATTATTCTTTGAAGATGATGCGATTGTATCGCACGAATTCGAAGCAATTGTAAAAGACAGTTTGAAGA  
15 AAGTTTCAAAAATGTTGAAATTTTATTTTATGATCATGGTAAAGCAAAAAGTTATTGCTGGAAAAAACAC  
TTGTCAAAAATTACCGTTTAGTTCACTATCGTAAACCCCTCTAAAACGTCTAAACGTGCAATCATGTGTACAA  
CAGCTTATTTAATTACTTTATCTGGCGCTCAAAAACCTCTACAAATAGCCTATCCTATCCGTATGCCGTGCTG  
ACTACTTAACTGGTGCTTTACAATTAACCTGGACTAAAGGCTTATGGTGTTGAACCACCTTGTGTATTTAAAG  
GCGCAATTTAGAAAATTGATGCAATGGAGCAACGCTAACAATGAAATTAATAAATAAATTAACAAATGTTAAG  
20 GTTGGGTCTAGGCAAAATATTTCTTGATAAAAAAAGCGGATTAAACAGAATAACAAATGTTCTAGAACAT  
CCTCTTCTCCGCCAAGACGGAAAAATTTGGGGATTATGTGGTGAGCTCATTTGTATTCCGTGAGATAAAAAA  
ATTTAATCCCCACATTAAATTTGGTGTAATTTGTACCAAAACAAATGCTTATCTTTTAAACAAATCCATA  
TATCGATCAACTTTACTATGTAAAAAGAAAAGTATTTTGGATTACATCAAATGTGGTCTAGCAATTCAAAA  
AGAACAATATGATTTAGTGATTGATCCGACGATTATGATTGTAATCGCGATCTTTTACTTTTACGCTTAAT  
25 CAATGCCAAGCATTATATTGGCTACCAAAAAGCCAATTATGGTTTATTTAATATTAATCTGGAGGGACAATT  
TCACTTTTCGGAACCTCTATAAACTCGCCCTTAGAAAAAGTGAATATTACGGTACAAAGATATAAGCTATGACAT  
CCCATTTGATAAGCAAAGTGCGGTGCAAAATTTCTGAATTTTTGCAGAAAAACCACTAGAAAAGTATATTGC  
TATTAATTTTTATGGTGCTGCAAGAATCAAAAAGTAAACAATGACAACATCAAAAAATATTTAGATTATCT  
CACGCAAGTCCGCGAGGAAAAAGCTGGTGCTATTAAGCTATCCTGAAGTAACAGAGAAATTAACACAAT  
30 GTACGCGGATTATCCGCATATTTTTGTCCATCCAACAACCAAGATCTTTCATACCATTGAATGATTCCGCA  
CTGTGATCAATTAATCTCTACAGACAGCTCTACTGTACATATTGCTTCAGGTTTTAATAAACCAATTATTGG  
TATTTATAAAGAAGATCCTATTGCGTTTACACATTGGCAACCCAGAAAGTCGGGCAGAAACGCACATACTTTT  
CTATAAAGAAAATATTAATGAGCTCTCACCTGAACAAATTGACCCCTGCATGGCTTGTCAAATAGTCTTATCT  
CTTCTGACACTTGGGGCAATAGAACTATTTCTGTTGCCCTATCACTAACTTTCTATTTTTGTGCCACATGT  
35 TGGACAAGGCTTATCCTTATTACCATAAAACCGCAATTTCTGGACAAAATAGCCTGGACGCCCCATCCGGTTG  
GAGAAAATCTTTTAGCGTCGTACCACCTTGTGGATTGCGTTAGACAGCACTTGTTTTTATTGTTCTACTAA  
CTGCCCACATTGTGCTTAGTTAACTCCCTGCTGTTTTTGGCGGATGTAGGTTACAAAGAAATAACGTTTC  
ATTTCGCATAGATATTTCCCAACGCCAACGACGACAGCATTATCCATTAAAAAAGTTTTAAGTGCGGTCTGTTT  
TTTACGACTTTTTTGGCCACAAGTAATCAGAATCAAATTCCTCAGACAGAGGCTCTGGGCCTAATTTAGAAA  
40 AAGAGGAAATTCGTTCACTTCTCTGTCCATAACCACGCTCCAAAACGACGAGGATCGTTATAACGCACAAC  
TTTTCCGTTATTCACTACGATATCAAGATGATCATGTTTATCAATAAGATCCCCTTTCTCCACAACCTCTCAA  
TGACCCTGACATCCCTAAATGTCCAATCATATAGCCTGTTTCAAGTTGGATAATTAATACTTCGCACGGCG  
ACTTAATGCGATGACTTTTTTGTGTGTAATTTGCGCTAATTCCTCGCTTACCATCCAGCGTAATTTGCGTTG  
45 GCGAACAACAATTTTTTCAATGATAGCCCCTTCAAGATAAGGGCTAATTCATTTTTTGTGGTTTCAACTTC  
AGGTAATTCTGGCATAGGTTATATATCCATAAATCTTATAATTGATAATATCCAACTATTATCATGCTATG  
ATTGGCAGGCAAAAAGCCGCAATCGCGTAAATATTTTTGTCCGCAAGTCAAACAAAGCAAGGAGTCCACAAG  
GCGTAATGCTTCCGCAGTAAAAGCTGCTAATGTATAGTTTCGCCCTCACATTATACTCATCAGGAATATCCAA  
AACACAAATATCAGAAATGCTGACGCAAGATTGATGATTACTCGCATAAACCAATGAAAAGATCAGCATAAAT  
CTGCTCAAAAAGCCACTCTGCGGTATTTCTGCTCTGTTGGAATAGTGATAGAATCCGGACCACCAACTATTGC  
50 CATTGCTTTTTCTTTTAATTCCGAGCCATAGCCCATATGCCGTTTTTCAATATTCGAAAATAATGCCAAAGT  
ATAATCTCCACAAGGATCTGCCTTAGGTGTGATACCTTAAGCGTAAGTGGGGCGACATCAATAATGTCAA  
CCAATTCATCATGGTGAGTAATCACCGATTTCTTTGCAATTAAACATAAACGATTGTAGCAAAAAGGCAC  
AAGTTGAATATGAGGATATCGCGCTTGTAATGCCTAAGATGCGCATATTGGCAGAGGCAACAAATCCAC  
TTTTCCCTTGTCTCAATGCGTTGGCACAACCAACCCGCGGTCCAAATTCATTTTCACTTGTAGGTGATA  
55 CTGTTGGATTAAATGCTTGTGTCATAACGTAAAAGGCTGGCGTAAACTCCCTGCGGCTAAAATCTCATGCG  
ATATGTTTACTGTATGGTAAAGATGGGGACTAAAACCTGCTGTTCTCAATCATAGAATATTTAATCGGTAC  
ATTATACGCTTGTTCATTAAGATTCGGTTAAATTTGACTGGCTATTCCATATTTCCATTGTTGGTTAGG

B45292

AGCGCTGACCAATCTGGGCATGGGCTATGTATTTGAAGAACTGATTGTAATTTAACTGAAGAAAATAACGA  
AGAAGCTGGCGAACACTTTACCCACGCGAAGTGATCGAGCTGATGACGCATTTAGTCTTTGATCCGCTCAA  
AGACCAAATTCGGCCATTATTACGATTTACGACCCAGCTTGCAGGAGCGGTGGCATGCTGACCGAGTCGCA  
5 AAACCTTTATTGAGCAAAAATATCCGCTATCTGAATCACAAGGCGAGCGTTCCATCTTTTTGTTTGGTAAAGA  
AACCAATGATGAAACCTATGCCATTTGTAATCTGACATGATGATTAAAGGTGATAATCCCGAAAACATCAA  
AGTCGGCTCAACCCCTTGCTACAGATAGCTTCCAAGTAATCACTTTGACTTTATGCTTTTCCAACCCGCCATA  
10 TGGCAAAAGCTGGAGCAAAGATCAAGCCTATATCAAAGACGGCAATGAGGTTATCGACAGTCGCTTTAAAGT  
TACCTTACCAGATTACTGGGGCAATGTAGAAACCCCTTGATGCTACCCACGCTCCAGCGATGGACAGCTGCT  
ATTCCTAATGGAAATGGTCAGCAAAATGAAATCGCCGAATGACAACAAAATCGGCAGCCGAGTGGCCCTCCGT  
GCATAACGGCTCAAGCCTGTTTACCGGCGATGCAGGTTTCAGGAGAAAGCAACATTCGTCGCCATATTATTGA  
AAAAGATTTGCTCGAAGCCATCGTACAGCTGCCTAACAACTGTTTATAACACAGGTATTACCACTTATAT  
TTGGTTGCTGTCCAACAACAACTGAAGCAGCAAGGCAAGTTTCAGCTCATTGATGCCAGCCTCTTATT  
CCGCAAAATTCGCTAAAAACCTTGGCGATAAAAACTGCGAATTTGTACCTGAACATATCGCCGAAATTACCCA  
15 AAACTATCTTGATTTCACTGCCAAAGCGCGCGAAACCGACAGCCAAAATGAAGCAGTCGGCCTGGCTTCGCA  
GATTTTTGACAATCAAGATTTTCGGCTATTACAAAGTCACCATCGAACGCCCGGATCGCCGTTCTGCCCAATT  
TACCGCCGAAAATATCTCGCCTTTACGGTTTGACAAGGCTTTGTTTGAGCCGATGCAATATCTTTATCGGCA  
ATATGGCGAACAAATTTACAACGCCGGATTTTTCAGCCAAACCGAGCAAGAAATTACCGCTTGGTGGCAAGC  
GCAGGCGATAGCTTAAACAACAAAAACAAGACCAAGCTGCTGGACGTCAAAACCTGGGAAAAAGCCCGCGC  
ACTTTTTAGACGGCATCAACCTTGCTCGAACATTTTCGGCGAACAACAATTTGACGATTTCAACCAATTCAA  
20 ACAAGCCGTGGAATGCCGTCTGAAAGCCGAAAAAATCCCCCTTTCTGCCACAGAGAAAAAGGCCGTTTTCAA  
TGCCGTAAGTTGGTACGACGAAAATTCAGCCAAAGTGATTGCCAAAACACTCAAGCTCAAAACCAACGAATT  
GGACGCCCTTTGCCAACGCTACCAATGCCAAGCCGACGAGCTGGCAGACTTTGGCTATTACGCCACCCGCCAA  
AGCAGGCGAATATATCTATATGAACGAGCAGCGACTTGCAGCAGAGCAAGTCCATACCGCTCAACAAAAA  
TATCCACGACTATTTTCAAAGCCGAAGTGCAAGCGCACATCAGCGAAGCATGGCTGAATATGGAAAGCGTAAA  
25 AATCGGCTATGAAATCAGCTTCAACAAATACTTCTACCGCCACAAACCATTACGCAGCCTTGCAGAAGTTGC  
CCAAGATATTTTGGCGTTAGAAAAACAGGCTGACGGCTTGATTAGTGAAATTCTAGAGGCTTAATAAAAAAC  
AACTATTAAGCAAGTTTTAATAGGCTTAAAGTAAGGAAATTCAAAATATATAACACATTGAAAAATAATGA  
ATTTTACCTTTTAAGCAAGATTTGGCATGAAATAAGCAAGGAATAATAATGACAGAACCCTTTCTAAAATT  
AACGGCATTATCACAAAAAATTTATTTAGAGATGCAAGCTGACGCGGAAAAACCAATATTTTGAGCGCAAAGGACTAGGA  
30 AAAAAAGACATCAAGCCAACTAAAAATAGCTGAAGAATTAGTTGGAATGCTCAATGCTGATGGCGGAGTTTTG  
GCTTTTGGTGTGGCAGATAATGGCGAAATCCAAGACTTGAATAGCCTTGGCGATAAATTAGATGATTATCGG  
AAATTGGTTTTTCGATTTTATTTGCACCGCCTTGTTCGGATTGGACTGGAAGAAATTCGGTTGATGGAAATTA  
GTTTTCTTATTCACGTAGAGCAAGATTTAGAGCGTATTTATTTGTGCGAAAGACAATGAAATGTGTTCTTA  
CGTGTAGCAGATAGTAATCGAGGCCCTCTCACCAGAGAAACAAATCAAAAATCTTGAATATGATAAAAAATATC  
35 CGTCTATTTGAAGATGAAATAGTTTCTGATTTTAAATGAAGAAGATTTAGATCAAGAATTATTTAGAGCTATAT  
AAAAAGAAAGTTAATTTTACCTCCGATAATATCTTAGATTTATTATACAAGCGAAATTTATTAACCAAAAAAG  
GAAGGTTGTTATCAGTTTAAAAAATCAGCCATTTTACTCTTTTCTACCATGCCGGAACGTTACATTCTTTCA  
GCATCAGTCCGCTATGTTCTGTTATGAAGGTACAGTAGCGAAAGTCGGTACTGAGCATAATGTGATAAAAGAC  
CAACGTTTTGAAAAATAATTTCCAAAGCTAATTGAGGAGCTGACCTATTTTAAAGAGCCTTTTAAAGGAT  
40 TATTACTTTCTTGATGTCATCAGGGAAAAATTTATCAAAGTACCGGAATATCCTGAAGAAGCTTGGTTAGAA  
GGTGTGTAAATGCGCTTTGTCATCGTTCTTACAATTGTTTCAAGGTAATGTTATTTATATTAACATTTTCGAC  
GATCGTCTTGAAATTAGTAATAGTGGCCCTCTCCCTGCTCAAGTCACCATTTGAAATATTTAAACCGGAACGA  
TTCGCTCGGAATCCACGTATAGCACGAGTTTTAGAGGATCTTGGGTATGTCGGTCAGCTTAATGAAGGCGTT  
TCCCGTATTTATGAGTCAATGGAAAAATCATTATTGGCAAAGCCTGAATATAGAGAACAAAACAACATGTT  
45 TATCTAACATTGCGCAACCGTGTTACCGCACATGAAAAACGGTATCTACAGCCACTATGCTGCAAGATTGAA  
AAAGAAATGGACAAACTACAACGACACCCAAAAAGCCTTTGCTTTATCTATTTACAAATGGTACGGCGATA  
TTGTACAGAAATTAGTTGACTATACAAAAATCAATCAGAATTCGATCCGAGCGTATTTAAATGCCTTTATTCAG  
CAAGGTATTATTGAAAGACAAAGTGTAACAGCGTGACCCCAATGCCAAATATGCTTTTTAGAAAAGATTAA  
GCAAGGTTTATCGCTTGCTAAGCAAGGAAATGACAATGCTTAACTTGCTGAAAAATAATGATTTTTATCTT  
50 TTAAGCAAGATTTGGCATGAAATAAGCAAGTTTTTTTTATAGTTAAACGGACAACAAATTGCATCAATAAGAG  
CGGTCAATTTTTAAGGATTTTTTGCAAATGAGACGATACGAGCGTTACAAAGATTTCAGGTGTGGATTGGCTA  
GGGGAGGTACCGAGCCATTGGGAGTTAAAACGCTTGAAACAATTTATTTGTTGAAAAAAAACATAAGCAAAGC  
CTGTCTCTTAATTGTGGAGCCATTAGTTTTGGTAAAGTTATTGAAAAATCGGATGATAAAGTAACAGAGGCA  
ACAAAACGTTTCATATCAAGAGGTGTTAAAAGGCGAGTTTTTAATAAATCCTTTAAACTTAAATTATGACCTA  
55 ATTAGTTTGAGAATTGCTTTATCAGAAATAGACGTTGTTGTAAGTGCCGGTTACATTGTTTTAAAAGAAAAA  
CAATAATTAATAAAAAATACTTTTCGTATTTATTACATAGATACGATGTTGCATATATGAAATTATTAGGT  
TCAGGTGTAAGACAAACGATTAACTATGGGCATATTTTCAGACAGTATTTTGGTTATTTCCACTCTCTCCGAA  
CAACAAAAAATCGCGCAATTCTCAGAGATAAAACCGCTAAAATCGATCAGGCGGTGGATTTGGCGGAAAAG  
CAGATTGCCCTGTTGAAAGAGCACAAAGCAGATCCTGATTCAAATGCCGTAACCCGAGGCTTAAACCTTGAT  
60 GTGCCGTTAAAAGATTCCGGCGTGGAATGGATAGGGCAAGTGCCGGAGCATTGGGATGTGCAACGTTCAAAA  
TTCATTTTCAAGAAAATAGAAAAGAAAGTGAATGAGGAAGACCAATTGTTACTTGTTTTAGGGATGGGCAA  
GTAACCTCTGAGAGCTAATCGAAGAACTGAAGGATTTACAAATGCGCTAAAAGAACACGGCTACCAAGGAATT

B45292

GCGAACGCTCCAGCTTCGATTTGCGCCTTCTCTAGAAAAATAAGAACGTATCTACTTCATCTAGCACCAATA  
 TTGCATTATCGGCTTTCGCTTGTTCAAAGGCTTGAGCAATATTTTGTCTGTCCCGCCACATAAGGATTAA  
 GTAAATCTGAGCCTTGTCTTAGCAATAGCGGCATGTCCAACCTGTTCCGCAAGCCACGCTGCCCCAAGCAGTTT  
 5 TTCTGTTCCTCGGCGGGCCATAGCAACAAATTCGCCCTTTTTTCGACCGTTTTTAACCTTCACTAATACGAT  
 GAATATTGTCGTTACAAGCCACATAATCCAAGTTGTAGTCGGCTTTCCTAAAAACAAGCGGTTCAATTTTCG  
 GTTTATTTTTCGATTTTAAACGTTTGATTAAACATCATGAGCAAAGTCTCAGCAAAATTTGATGTATTGAGTT  
 CCTTTGCCACCCGAATTGTGCGGCTTAAAAATCGCCGGCGTTAATGACCGCACTTTAGCAAAATGCTGCACAT  
 AGGCCGGACTTAATTTTCCCTCAGTCAGTTGCGTAATCAGTGCTGACTTATTTTTCAACGGCAAATCTGGCA  
 10 TTTCTAAAAATAAAATCAAAGCGGCGTAAAAAAGCAGGATCTATGCCGAAACAGAGTTAGATAACCAAATCA  
 TCGGCACGTTATTGTTTTCCAATAACTGATTTGTCCACGCTTATTTTTTTTGTGCAACAGAACGCTCCATAA  
 ACGAGCCGTTAAACACATCTCAATTTTCATCAAAAATTAAGCGCCTGCTTGCCTTCAATAGCGTTTGAG  
 CAAGACGACTGTAGTTTCAAGCGTTGCTCTGCCTCCACAACATCTCCGTCAAGAACCATGTAAGTAATGTTAT  
 ACGCCGAAATCCCCAACGCTGTGCAAGCAACCCGGCGAATTCTGTTTTACCAGTGCCAGGCACGCCATAAA  
 15 TTAAGAGATTACGCGCTTTTCGATGATGTTTTAGTGCTTGTGCAATAAGTCAACATCATCTCTTTCATGC  
 CGGCAATATGGTCAAATCATCCAGTTGCAGACTTGGCACTTGAGCGACTTCCGTACAAGATTTTAATAGGA  
 CGTTTTTCGTTAATGGTTGTGTACAAATTCATCAAAATCTAAGGTTTCGCCCCAATCTAAATAATCATGCA  
 CACTATCGGGGCGATAATCGCGATCAATCAGGCCATAAGCATCGAGTTTACTGCCTTTCTTTAAGGCAGATA  
 GAATCTGATTTTTTCGGCTGTTAAGTAAATCCGCCATGATCGCAGCCGTTCTTTGTAAATCCGATTTTCGGCA  
 20 AGTAGCCAAACAAATCTCGCATAGCTCCTTCACTACGTAAATGCATGGCAAAGCGGAGAAGTTCTGTTCAA  
 CGGGATTAGTTGCAAAAATCTGCCAACGTTGCCAAATTTTCATACGCTGTTTCCATAACTCAGGTAAAA  
 GTGCGGTGGATTTTTGGAGTTTATATACCGCTCTTTTAAAAGCCGACGAGCAACCGTGCCTAAATTTTTAT  
 CATTCTCTAATTCTTCAGGCAGCCCAAATGCACCTGGCAATTTTCATCACTTCGCCAGCTAGTCTCCGAAACA  
 CTTCCGAAAAACCTTTATGCTCAAATAAAATTTAAGCATCATATTTTCAGTATAAGAACACACTGCGGTG  
 25 GGTAAATTTATATTCAGACATAAAAAATCTCCTTACTGGTTGGTAAGGAGTATTTTAGTGAGTAGTGC  
 GACAAAGGTTCGTTAAGGATAGTTTTAAGAAGCTTTGTTAATCAACCATTCACTAAACCAGCACTAATT  
 ACAAGCTCTGCCATTTTTCGGCCATTTACAAGCTTAATTCCTTTAGCTTGATATTGTTTTTCATCTATGTTT  
 TCTAAACCAGAATGATATACGTAATACATTTCTGAATAACCATAGTTTTTATATTCACTTTCAAAGTTCGAA  
 ACATATTTCGTCTAATTGTTTAAATATCCGTATCTGACTTAATTTGCACAAATACTCTCTCTGCGTTGAAGAC  
 30 GAATACAAATCAAGATCTATTCCTTTCTCGTTTACCTAAAAACAGAGTATCGTTGCCATCCTAATTTAGAA  
 AAAACAAGATCCGTTAAAGTTCAAAGTCACTCCACCATAAACCTTTAATTAATTTTTCACTGATTTAATT  
 AATGTTTCATAACGCTCTTTTCGCTTCTGTAATTTCTCAATAACTTCACCATTATACGACGTATTAAATAG  
 TCCTCCATCTCAACACCACAAATCGTCCCTCTATAGGCTTGGACCTTTGTTACTCTACCATCAAGATTATCG  
 ACTAAAAGCTCTTTACCGTTAGCATCAACGCAAGACCAATTCCTCATGTTACTAATAACTTTTCTGTTCTA  
 35 GAACCATCGCTTTTCCCAACAACTCTTTACTGCAAAAAGCCCAATATAATTTACGTCCAAGAAGGTGATC  
 CAAAGTGTATCTTCCCAAGTTGATAAAAAATCTGAATTTGTCTCAAGTGATTTGAACAGTTTCTGTATGG  
 TCACTCCAATAAGTTTTACAATATTCAATACAACTATCCCATTGATTATTCAAACATTCTTTGTGAATCTCT  
 GATGTAGATTTCATAGCCAAGACGAATCGTATTTTTTGTACTTGCTGTACTATTTTTATCAATACAATCTTTT  
 TCCCAACATCTTTTATGCCTAATTTAATAAAACGAATATTAGTAGGTTCAATTTTTTCAAACATAGTTTTT  
 40 CCTATTTCTAGTTAAATTCACCGAATTATAGATAATTGAGCAAAAAAACAATTTAAACATATTTTTT  
 ACTCAATAATAGAAATGACAACAACTACCGACAAATCATCCGAAACGATTGCTTCTCAATCATCTTGCAGC  
 AAACCGTAAGCGGATATTTATCATCGGGATATTTTCGCCAAATTTTTTCGCGCATTTTCATCTGAAAGCCCGT  
 CGGTCAAGCCGTCAGAACAAAGTAATAAACTTTCCCTTGTGTAATTTCAATTTCTTGATAAAAAATTTTAT  
 CTTGAAATTCGGAATAATCGGCGACTAAACAAGAAGAACGCCGCCATAAATCGTGGCAAAATCTTCTCTT  
 45 TTTTATCGGGGAAATCAGTCAATAATTAGAAAGAAATAGAAATGATCTTGGGTGATTTGTTGCCATTTTCTT  
 GGGCATCAATTAAATAAGCACGACTATCGCTACGCTGAGAATTTTCGCTTTACGGGTATTGATCAATTT  
 CGGCAGCCACAAATGTGGTCCGCGAACCAAAATTAATCTCAGCTAATTTCTGCTGATAAACTGGATGTAAAT  
 CGTAGATCGTTTGACGGTTTATACTTTCCATTTGGCTTAATAATTGCATAGCCAATTTGCTCGCTTTTTCAG  
 50 GTCGGTTGCTATTAGAAATACCATCTGCCACGCCCAATAAAGTGCAGTCCGTTTTCAGGCGTTTTTCAG  
 CCGTTTTGAGTTTATATTGAAACACCGCTCGCCATTAAAAAGGGCATCTTGGTTGCGTTCGCTTGTGCTGC  
 CAATTTTGTGTTGGCAAAGGGTAATTTTCGCAAAAATTTTTCAATTTATTCAACCGCTTGTGAGAAGGATTTAA  
 AGGCGATCAATCGCTTTTAGTGATCTAACGCTTTCAATTTCTTAGACTTAAAAAAGTGCATTTTCGGGCACG  
 55 CCTGCTATCTTGTGGGGTAATACGGGATAACCCCCCTTTTTTTTTGCTTTTCGCGGTACGTTTCAGAAATC  
 CACGCACAGTGGAAATGGCTTTTCTGTTCCAGTTTCGATAACGACGAGATTTTGCACTTCTTTTAACCACGA  
 TTCTAACCGCACTTTTTTAAATCCTGATATTGACTTGACATAACTCCAATCATTAAACATTAGTACATTTTG  
 ACGAGCAAAGCCCCACAATAAGGCAAAATGTGGTTTTTCACTGGTTAAACATAAGTTTTTCAATATCCACGAC  
 AGGTTGAAAACCTTGATGCAGACCAACTTAATCCTCGACAATTATTGACACATTGAAGACGCTCCAAGTACC  
 60 ATGTACTTCATAAAGCATGGCTATCATTAACACCGCTTTTGAATAATGCCCATCAACATTCTGGTAAAC  
 AAAATATCCATGAGGTTTATCTCCCGCCAGCATTTTAAATCTGATACCTTTCGTGAGGAAGAGTATTTTCG  
 GTATTGAACTAATCGATGCCCATAAACCAATAGGCTAGTTTCTGATTATGCTTATAAGCTAGTGGCGTTGC  
 GATCTCTTCAAAGATATATTATGTTCTTTAAACATAGGATAAGCATTCAAAATCCGCCAACGCTGCGGAA  
 ATCGGGAAGCCAGAATCCACGCTCATACCCGACAGCTGTAATTAATAATGCCATCCGCTTTGCGGATAAG  
 TTCCACTGCATAATTCAAATCATTTTTTCATAATACTTTTCTCTGCCATTTTTTCATGATGAAATAATACCC

B45292

ATCTGTTGTAAATAATCTTGGGGTAGGAAAGCGCCAACCAAATTCGACGACCTTGATAGAAAAGCATCCC  
TTGTTTGTTCATTATAAGTTTCTCCTTTTGGAGATTGCCCCATAACGACATCATAACAATCGCCAATCGT  
AGATAATCCCACCCCTTCGGCACTTCAACCCCATCAACCTCCACCATCTCACACGGAAACGCTTTGGCGGT  
TTCGGCTAGTTTCGGCGTAGCGGTGAGGCTGTGTTTGTGAAAGTGCGGTGAGTTCTTCGGGTGTTTTCCGCT  
GATTGCCCTGCATGGCGGCAAGTTCTGCTTGTTCAGGCTAAGACCGTCTGAAAGGGCTTGGATTTGGCAG  
CACGGGATCGAAATCGACAAACACAGCTTTTAAACAGGGCTTGGCGGATTGTTCTAAGGTTGGTTGATTTG  
AGTGTGAGTTCTATTTTTGATCTAAAGTATTTAGAATATATCCAATTTCTTTTGCTTATTTATATCTAG  
AAGTAATAATTTAACTTTACTTAAAGCTGATACATATAGATTTTTTTGGACACTACCTTCAGCTAAAGTTTC  
AATTTGTTCTTTGCTATTTAATAAGGTATAAAAAATAAATAATGGGTTACAAATATTTTCATTAACTTTGAT  
ATTAATTACAGCTCTATTTCCACACATGTAATCTTTAAGATTCCAATTCGTCCAATAGTTCCTGATTTGCT  
AATTGCTAAACTATCTGGTTCAAATAACAGCACTCTTCTTTGCACTTAAAAATCCTTTTCTGTTTAAAGT  
TTGAGAGGTTTTATATACAAACCATGTTTAAATCTGTTGCTCTCAACCATTAATTGTTCTCCCAAAGTA  
GCTTGGTTTCAATTTTGTATGGATTAAACATAACCTTCTTGAAATGAAGCGCAATCAGCTAAAGTTATAACCTT  
CCAATCATTAT

**SEQ ID NO:79 polynucleotide sequence comprising orf25 and non-coding flanking regions of these polynucleotide sequences.**

CACGCTAGTGCCGCTCAATCCGACGCGACTGCGTCGCAATCGGTTAATCATAAGTGAGTGGCGTTGCCACT  
CGTGTGGGAGAACACAGCCCCAGCGGGGCTGAATTATGCGTAACCATGTACGGCTTTGCCGTGCATGGGAA  
AAAATAAGCGGTGAAATCTTGCAAATTTTTGCAAAATCTTACCGCTTGTTCTTTTGAAAAAGCATTAAAA  
CTCATCTAAATCATCTTCATGATTCATTGATTTTTTATGTGCGGTATCCATTCTTATATTTAATTGCAAGTTC  
CATATAATCTTTATTTCTAAGTTCTTCATCTTCAGCTATTTTTTCAATTAACTATTTACTTTATCCTCATC  
TCCACAAATTTTAATTAAGGCATCCCAAAGTAGAATTTTCTCTCTATGTATTTGTAGGATCATCCCTCTTTG  
AGATTTACGTTCGTATATTGAAGATTTAAGTAATGATAAAAAATACTTCAGGGGAACCTTAATATATCATCAGA  
AAAAGGGTTTCCAATTGAAACAAAGAAATAGATTATGTGACAAATATAGGTTCCGTGCAAGTTCTTTAAT  
TGTTGACAGAGCAATATTTTAAAAATATTTCTCCAAGTCTTTTGCATCCGATTGCACTACTAATTGATG  
ACCTCGGCCCTCTCGATATCCAATAATCTTACAATTTGATATTGCCCATATAGATCGCTAGAATTTAATAG  
TTGAGTAATAACTTCTTTTTTATCCTTCTCAGGAAGTCTTCTAAGTAATCTATAAACTAAGCGACTCCAAAC  
CATATCCGCCCCAAAGTCAAAGAATCCTAATTTCTTTTTCAGGCACCTCTTGGTAAATTTCTATATAATGTTGG  
TATAGTTGCTAGAGCTATTTCTTTAGTAAAGTCTTTTTTCATAGTCAATTAAATTGTTAACTACATTTTCTAG  
AGAATCGTCAGGAACAGCTGATAAAGCGATCTTGAAATCTTCTCTGACTGCATTGCAAGCCAAACTTTTTG  
TGATAATTTAACATTTTATGAAGTCAAGACTCAAACTTGTTCAAAATATAAATCAAAGAATGCCGAATAAGC  
AATCCTTCTATTTTATAGGAATTCATTATTTGAATTTATATTATCAATATCAAATAAACTTCTAGAAAAGA  
CTCATACATTTTATTATCTTGAATAAAATCACTTAACCTTAACCTTTTCTTTTGTGATTATCTGATCGTGCCAA  
GAGATAATCTTTAAGTTCAAAAATTTCTTTAAATTTATCTGGAAGAAAATTTCTTATCGCTTCAATAGTGAG  
TAAATCAACCACATCAATTTCTTTACCTAATTTGTTTAAAGATATTCGATAGAGAAGATGTGTAACGCTTAAT  
ATCTCGAATATTTTTTATTGTTGGCTTAATGATATTTCCAATATGCAATTAGACCAACGCGCTTATAGGTA  
AACATCCCTTAAAAATCTTATCTAAAGATGAAAAATAAATTTTCTTGTAATAGTTTTTTAGGTACCTGTGGTAT  
ATCGAATGGAATCTGAATTATCTTCTCTAAATAATCCTGGCCATCAATGGTATTATCATTTAATGGTTTAAT  
TACTCTATTTTTTATCAAATGATAAAACATAAACAATATTAGGAAAGTTTCTGTAACCTCTGACCAATTTTAG  
AATTGATTGTAATTCATCAGATGATAAACGGTCTATATCATCTAAAATTACAGTAATAGGTTTACTTATTTTC  
CTTTAGAACTTTAATTAATTTATCACGTTGATTTTTCAAACGTGTTTTTTCTTTCTTTTGTGAAAAAAA  
ACTTAAACAGCCACCCAAGACACTAAAATAAATTTCTTCAAAATGGAATAGGTTTTTAAATTAGATAACAACCTC  
TCCAAAACACTACTCAAACATCAATTAGCTCATTATCATCTCATAATCTCTTAACTGAGCAGAGATTTTCAGT  
AAAAAATAAAGCAACTAAGTTATGAGCATCACTAAACATCCAAGGATTAAATCAAGTACAAAAGAATTTTTT  
TTCTAATTTCTGGTCGCATTAATTTATATAGGATGTTTTACCATTTCCCATTTCTCCACATAATCCCACAAC  
CAAACCTTCTTTATAGTCAAAATGAAAAATGTGTTTAGCAAATGCTTCTGCACTACTAGCTCTACCTAATAA  
ATCATTGCTAGAATCTTTTATTGGATTATCGCTTATTAATTCATATATTTTCTTTTAGTAAATGCTCATAT  
CTTTTATGTGTAACC

**SEQ ID NO:80 polynucleotide sequence comprising orfs26, 27 and non-coding flanking regions of these polynucleotide sequences.**

TTATTGAATTTCCCTGGCAGAGAATAATATGACAAAAGTTTAGACAAAATTGCAAAACAATTAAGAGATTCT  
GATAAAAAGGTTAATCTAATTTACGCCTTTAATGGAAGTGGAAGAACCCGTTTATCAAAGTCTTTAAGAAT  
CTTATTGCACCTAAAGAAAATCATGCAATGAAGAAGATCTAACACGAAGAAAATTTCTTTATTTCAATGCC  
TTTACCGAAGATTTATTTCTATTGGGATAATGATCTACTAATGACACAGAACCAAAATTAAGATTCAACCA  
AATCTTTTATTTCGCTGGTTGATTAGAGATCAAGGGGATGAAGGTAAAGTAATTGGAAAATTTTCATCATTAT  
TGTGATGAAAAACTTATGCCTAAATTTGATATAGAAAATAATCAAATTACATTCAGTTTTGCACGTGGAGAT  
GATACGCCTGAAGAAAATATAAACTATCGAAGGGGGAAGAAAGTAATTTTATTTGGAGTATTTTTCATACG  
TTAATTGAACAAGTTGTTGCAGAATTAAATATCTCAGAGCCTAGTGAACGCACTACTAATGAATTTGATGAA  
CTTAAATATATCTTTATTGATGATCCAGTAAGTTCATTGGATGAAATCATCTTATTCAATTAGCTGTTGAT

B45292

AACTCATCTCTTAAACTAGTGTATTACTCCATGTTTAGTCACTAGCCATAGTGCGAATTTATCATATTTA  
TTTCTAGGATTTTCTAAGATCGTTTCAGGGAAGAAAGCATATGCTTGAGCAATTAACATATCTCGCTCATAT  
TTTTCTATTACCTTCCAGTGTCTAAGTTTGGGAGGGGCAATATCATCTAAACATTTGTTTGAAGTCCACCAT  
5 AAACCTTTACCTTCTATTAAATAGAGATTTATAGTATTTAGCTACAGGAGTTATTGGATTATCTAATTCTCGG  
AGAGAATCATATGTGGTCTCCATTTTTCAAATATGCTCTCCCCCTTTCTAATAACATATCTATTTTATAT  
CTAGGGTAATGGGTACAGCTATATCACATAAACACGACTCATATGGTTTGGATAGGAATTTAATATTTCCA  
CCTAATTTACCAATGTAAAGAAAATTTTTCTATATTTGGAATTCGTGTAGACTCAAGAATAGAAGTCCCA  
ATTGAAGTCCATTTATCTCCTTGTGTACTTTTTTACTTCAATACCATAATATTGACTAGCTACAATGTCTGGA  
10 AAATGTTTCCCTGATACTAACTAATAGTGTCTTCGAAAGGAGTATTTGAGCACAATAACAAATAGCCTCA  
TATACATCTTTTTCTAATCAATACCCTACGTTTCTTATAGTATGCAACCTATTTTCTGCATCATGATTA  
AGAAAATTATCGACTCTATTCATTAATGACGTGAATTCATGTAAAGGTGGATACTTATTTTATAGAGAAAATC  
ATAAATAAATCCTATTTTAAATAAAGATTCCATTTTTTTCTATATTTTATAGCAATATTATAAGCTAATATA  
CATGGTACCGCATTTGCCAATAATTTTATAGGCATTACTGGCTGAAACAGAAACGTTTTCTGCTGTTTTAGGT  
15 AAAATAAATTGGTATCTATCAGGAAACGTTTGTAACTTAGCACATTTCTTTATAGTAAGACGACGTTTCGAGC  
ATGCCCTTAGATAAATTCGTTAATATATTTCCCTTCATGCTCTATGCTTAGCCTACGATTTTCAATATTACCA  
TGATGTTTCAAGATCGGAATTGTTGGGGCCCAACAGAAATTAAGTTTAAATTTTCAAACCTGGCCCTTGG  
ACCAATGGGTTTTCCCCCATAAATTATTTGGGGCTTTTGGGGAAATAAATTTTTTGGTTTTGAAAAAAGGGGT  
TCTTTTGGTTTATAAAAAATTGGGGTTTTCTTTTGGGAGGAATTTATATTAATAAGGGCCCTTTGGGGGCG  
GCCATTGGGTAAACCAACCCAGACTTTTTC

**SEQ ID NO:83 polynucleotide sequence comprising orf33 and non-coding flanking regions of these polynucleotide sequences.**

ATGTTAAGGCTTGAGGCAAAGAATGGGCTCAAGCCTTTTGATTTTCATCAAAATATAAAAAATTAAGGAGATTA  
TATGAGTGTACTCAGTTACGCACAAAAAATCGGTCAAGCCTTAATGGTGCCTGTGGCAGCCTTACCTGCTGC  
25 TGCATTATTAATGGGTATTGGCTATTGGATCGACCCAGATGGTTGGGGTGCAAAATAGTCAATTAGCCGCATT  
ATTAATTAATCTGGCGCAGCAATTATTGACAACATGGGCTTACTCTTCGCTGTGGGCGTCTGCTTTTGGGCT  
TGCAAAAGATAAACACGGTTCCGCCGCACCTTTCAGGCTTGTGGTCTTACGTAGTAACCACCCTACTTTC  
CCCTGCTGGTGTAGCACAATTACAACACATTTGATATTAGTGAAGTGCCTGCCGCATTCAAAAAATCAATAA  
CCAATTTATTGGGATTTTAATTGGTGTGATTTTCACTGAACCTTTACAACCGTTTCTATCAAGTTGAATTACC  
30 AAAGGCACTTTTCTTTTAGCGGAAACGCCCTCGTCCCAATTTTGGTTTCTTTCGTGATGATCGCCGCTATC  
ATTTGCCTTACTCTATTTTGGCCTCATATTTTAAACGCTCTCGTTTCATTTGGTGAATCCATCAAGATTT  
AGGTGCAGTAGGTGCGGGGATCTACGGTTTCTTCAACCGCTTATTAATTCCTGTAGGCTTACACCATGCCTT  
AAACTCTGTATTCTGGTTTGTATGTAGCGGGTATCAACGATATTCCAACTTCTTGGGCGGCGCTAAATCCAT  
TGCCGAAGGCACTGCAACCGTGGGGCTAACTGGTATGTATCAAGCTGGTTTCTTCCCTGTCATGATGTTTGG  
35 TTTACCAGGTGCTGCTCTTGCAATTTTATCACTGCGCAAAACCAAACCAAAAGTACAAGTGGCCTCAATTAT  
GCTTGGCGGGTGCCTTAGCCTCTTTCTTTACAGGGATCACTGAACCGCTTGAATTCTCATTATGTTCTGTTG  
ACCTGTACTTTATGTATGTCATGCATTATTAACAGGTATCTCTGTATTTCATTGTCAGCTACAATGCCTGGAT  
TGCGGATTCGGATTAGTGCAGGTTTGTAGGATATGGTACTTTCTAGCCGTAACCCACTTGCCGTTAGCTG  
GTATATGTTACTTGTACAAGGTATTGTATTCTTTGCTATCTATTATTTTGTGTTCGGTTTTGCAATTAATGC  
40 CTTTAATCTCAAAACGCTAGGACGTGAAGATAAAGCGGAAACAGCTGCAGCCCCAACTCAAAGCGACCAATC  
TCGCGAAGAAAGAGCGGTGAAATTTATTGCTGCTTTAGGTGGTTTCAAGAACTTCAAACCTGTGGATGCTTG  
TATCACTCGTTTACGCTTAACTTTAGTTGATCATCACAATATTAACGAAGATCAACTTAAAGCGCTTGGTTT  
AAAAGGTAATGTAAATTAGGCAATGATGGATTACAAGTCATTTTAGGGCCTGAAGCTGAACCTGTGGCAGA  
TGCG

**SEQ ID NO:84 polynucleotide sequence comprising orf34 and non-coding flanking regions of these polynucleotide sequences.**

GGGATTTTCATTATGCTGTTTTACTTTTATACTTTAAAGTGCAAAAAATAAAAAACTCTTTTTCGCTAAACGG  
AATAATAAAATGAAAACAACCTTCTGAAGAATTAACGGTATTTGTGCAAGTAGTCGAAAATGGCAGTTTCAGC  
CGTGCGACCAAGCAGCTATCAATGGCAAATTCGCGGTAAAGTCGTGTGGTGAAAAGGCTAGAAGAAAAATTG  
50 GGTGTGAACCTAATCAACCGCACTACTAGACAGCTTAGACTAACAGAAGAAGGCTTACAATATTTTCGTCGC  
GTACAGAAAAATCTGCAAGATATGGCTGCAGCTGAAGCTGAAATGTTGGCAGTGCACGAAGTCCACAAGGC  
ATACTACGCGTAGATTACGCCATGCCGATGGTGTACATCTGCTAGTGCCACTGGCAGCAAAATTAACGGAA  
CGCTATCCGCATATCCAACCTTTCGTTAGTTTCTTCTGAAGGCTATATCAATCTGATAGAACGCAAGTCGAT  
ATTGCCTTACGAGCTGGAGAATTGGATGATTCTGGGCTGCGTGCTCATCTATTTGATAGCCACTTCCGC  
GTAATCGCCAGTCCAGACTACTTGGCAAAACACGGCACGCCACAATCACTGAAGCTTGTGCCAACCATCAA  
55 TGTTTAGGCTTCACTGAGCCCAGTTCACTAAATACATGGGAAGTTTATAGATGCTCAAGGAAATCCCTATAAA  
ATCTACCGTACTTTTACCGCCAGCAGCGGTGAAATTTTACGGTCATTGTGTCTTTTACGGCTGTGGTATTGCT  
TGCTTATCAGATTTTTTGGTAGACAATGACATCGCTGAAGGAAATTAATTCCTTACTTACTGAACAAACC  
GCCAATAAAACGCTCCCCCTCAATGCTGTTTACTACAGCGATAAAGCAGTCAACCTTCGCCTACGTGTGTTT  
TTAGACTTTTTTAGTAGAAGAGCTAAGGGGATAATTAAATTCATAGCATTGAATTTTAAAGTCAATTTGCAA

**CLAIMS:**

1. An isolated polypeptide comprising an amino acid sequence which has at least 85% identity to an amino acid sequence selected from the group consisting of SEQ Group 2 ,  
5 over the entire length of said sequence from SEQ Group 2 .
2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 95% identity to an amino acid sequence selected from the group consisting of SEQ Group 2, over the entire length of said sequence from SEQ Group 2 .  
10
3. The polypeptide as claimed in claim 1 comprising an amino acid sequence selected from the group consisting of SEQ Group 2.
4. An isolated polypeptide of SEQ Group 2 .  
15
5. An immunogenic fragment of the polypeptide as claimed in any one of claims 1 to 4 in which the immunogenic activity of said immunogenic fragment is substantially the same as the polypeptide of SEQ Group 2 .
- 20 6. A polypeptide as claimed in any of claims 1 to 5 wherein said polypeptide is part of a larger fusion protein.
7. An isolated polynucleotide encoding a polypeptide as claimed in any of claims 1 to 6.
- 25 8. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 85% identity to an amino acid sequence selected from SEQ Group 2 over the entire length of said sequence from SEQ Group 2; or a nucleotide sequence complementary to said isolated polynucleotide.
- 30 9. An isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide selected from SEQ Group 2 over

17. A process for producing a polypeptide of claims 1 to 6 comprising culturing a host cell of claim 16 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

18. A process for expressing a polynucleotide of any one of claims 7 – 14 comprising transforming a host cell with the expression vector comprising at least one of said polynucleotides and culturing said host cell under conditions sufficient for expression of any one of said polynucleotides.

19. A vaccine composition comprising an effective amount of the polypeptide of any one of claims 1 to 6 and a pharmaceutically acceptable carrier.

20. A vaccine composition comprising an effective amount of the polynucleotide of any one of claims 7 to 14 and a pharmaceutically effective carrier.

21. The vaccine composition according to either one of claims 19 or 20 wherein said composition comprises at least one other non typeable *H. influenzae* antigen.

22. An antibody immunospecific for the polypeptide or immunological fragment as claimed in any one of claims 1 to 6.

23. A method of diagnosing a non typeable *H. influenzae* infection, comprising identifying a polypeptide as claimed in any one of claims 1 - 6, or an antibody that is immunospecific for said polypeptide, present within a biological sample from an animal suspected of having such an infection.

24. Use of a composition comprising an immunologically effective amount of a polypeptide as claimed in any one of claims 1 – 6 in the preparation of a medicament for use in generating an immune response in an animal.

# **ABSTRACT OF THE DISCLOSURE**

5 The invention provides BASB231 polypeptides and polynucleotides encoding BASB231 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.